###begin article-title 0
###xml 29 42 29 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1 and BCRP</italic>
###xml 89 97 <span type="species:ncbi:9606">patients</span>
CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age
###end article-title 0
###begin p 1
###xml 176 180 176 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 181 186 181 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ABCB1</italic>
###xml 392 396 392 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 398 402 398 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRP1</italic>
###xml 404 407 404 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRP</italic>
###xml 408 411 408 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MVP</italic>
###xml 417 421 417 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 603 607 601 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 612 616 610 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 643 647 641 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRP1</italic>
###xml 652 655 650 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRP</italic>
###xml 734 735 732 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 744 745 742 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 755 756 753 754 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 769 770 767 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 788 792 786 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 833 834 831 832 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 844 848 842 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 853 857 851 855 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 901 902 899 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 921 925 919 923 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRP1</italic>
###xml 930 933 928 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRP</italic>
###xml 940 941 938 939 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1036 1040 1034 1038 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 1057 1061 1055 1059 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 1062 1066 1060 1064 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 1256 1265 1254 1263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1/BCRP</italic>
###xml 1335 1336 1333 1334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 507 515 <span type="species:ncbi:9606">patients</span>
###xml 1413 1421 <span type="species:ncbi:9606">patients</span>
Clinical resistance to chemotherapy in acute myeloid leukemia (AML) is associated with the expression of the multidrug resistance (MDR) proteins P-glycoprotein, encoded by the MDR1/ABCB1 gene, multidrug resistant-related protein (MRP/ABCC1), the lung resistance-related protein (LRP), or major vault protein (MVP), and the breast cancer resistance protein (BCRP/ABCG2). The clinical value of MDR1, MRP1, LRP/MVP, and BCRP messenger RNA (mRNA) expression was prospectively studied in 154 newly diagnosed AML patients >/=60 years who were treated in a multicenter, randomized phase 3 trial. Expression of MDR1 and BCRP showed a negative whereas MRP1 and LRP showed a positive correlation with high white blood cell count (respectively, p < 0.05, p < 0.001, p < 0.001 and p < 0.001). Higher BCRP mRNA was associated with secondary AML (p < 0.05). MDR1 and BCRP mRNA were highly significantly associated (p < 0.001), as were MRP1 and LRP mRNA (p < 0.001) expression. Univariate regression analyses revealed that CD34 expression, increasing MDR1 mRNA as well as MDR1/BCRP coexpression, were associated with a lower complete response (CR) rate and with worse event-free survival and overall survival. When adjusted for other prognostic actors, only CD34-related MDR1/BCRP coexpression remained significantly associated with a lower CR rate (p = 0.03), thereby identifying a clinically resistant subgroup of elderly AML patients.
###end p 1
###begin title 2
Keywords
###end title 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 232 236 232 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 329 330 329 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 331 332 331 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 636 637 636 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 639 640 639 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 641 642 641 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 892 893 892 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 894 896 894 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 1080 1084 1080 1084 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 1086 1090 1086 1090 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRP1</italic>
###xml 1092 1095 1092 1095 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRP</italic>
###xml 1101 1105 1101 1105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 977 985 <span type="species:ncbi:9606">patients</span>
###xml 1314 1322 <span type="species:ncbi:9606">patients</span>
Clinical resistance to chemotherapy in acute myeloid leukemia (AML) is often associated with the expression of (membrane) transport-associated multidrug resistance (MDR) proteins. Expression of P-glycoprotein (P-gp), encoded by the MDR1 gene, is an independent adverse prognostic factor for response and survival in de novo AML [1-4]. Moreover, it has been shown that besides P-gp, also the MDR-related protein (MRP1/ABCC1) and the lung resistance-related protein (LRP), also designated as the major vault protein (MVP), are expressed in AML. However, the prognostic significance of the latter resistance proteins has not been settled [3, 5-7]. Some years ago, a new drug resistant protein, i.e., the breast cancer resistance protein (BCRP/ABCG2), which is the equivalent of the mitoxantrone (MXT) resistant protein and the placental ABC transporter (ABCP), was found to be expressed in AML [8-13]. The precise role of either resistance proteins among poor risk AML such as in patients of older age has not been established. This study prospectively investigated the relevance of MDR1, MRP1, LRP, and BCRP messenger RNA (mRNA) expression in combination with known prognostic characteristics like CD34 expression, white blood cell (WBC) count, and secondary AML as possible denominators of response and survival in patients with AML aged 60+ who were treated in the same clinical trial.
###end p 4
###begin title 5
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and methods
###end title 5
###begin title 6
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 6
###begin p 7
###xml 329 331 329 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 521 523 519 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 1013 1015 1009 1011 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 15 23 <span type="species:ncbi:9606">patients</span>
###xml 96 104 <span type="species:ncbi:9606">patients</span>
###xml 368 376 <span type="species:ncbi:9606">patients</span>
###xml 750 758 <span type="species:ncbi:9606">Patients</span>
A group of 154 patients with AML aged 60 years or older were included in the present study. All patients were enrolled between May 1997 and February 1999 in an international, multigroup, randomized phase 3 trial performed under auspices of the Dutch-Belgian Hemato-Oncology Cooperative Group and the UK Medical Research Council [14]. In that trial, 419 eligible white patients >/=60 years with previously untreated de novo and secondary AML (M0-M2 and M4-M7 according to the French-American-British [FAB] classification [15]) were randomized to receive two cycles of induction chemotherapy consisting of daunorubicin (DNR) and cytarabine (ara-C) with or without the P-gp inhibitor PSC-833 (Valspodar, Amdray(R); Novartis Pharma, Basle, Switzerland). Patients in both arms in complete remission after these two cycles were to receive one consolidation consisting of ara-C, MXT, and etoposide. Inclusion criteria, clinical characteristics, treatment, and outcome of the phase 3 trial have been previously reported [14].
###end p 7
###begin p 8
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 152 160 <span type="species:ncbi:9606">patients</span>
###xml 289 297 <span type="species:ncbi:9606">patients</span>
Bone marrow (BM) aspirates had been collected at diagnosis for the analysis of P-gp function and expression, as described previously [14]. Selection of patients for our study was based on availability of sufficient purified AML blast samples in our tissue bank, which was the case for 154 patients.
###end p 8
###begin p 9
###xml 196 204 <span type="species:ncbi:9606">patients</span>
This study was approved by the ethics committees of the participating institutions and was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all patients before randomization.
###end p 9
###begin title 10
Methods
###end title 10
###begin p 11
###xml 153 154 153 154 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 322 324 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 496 500 <span type="species:ncbi:9913">calf</span>
BM aspirates were obtained in heparinized tubes. Mononuclear BM cells were collected by Ficoll Hypaque density gradient centrifugation (density 1.077 g/m3; Pharmacia, Uppsala, Sweden). To obtain purified samples with more than 85% of blasts, T-cell depletion and adherence depletion was performed as previously described [16]. Cells were cryopreserved in Dulbecco modified Eagle medium (DMEM; Gibco, Paisley, UK) supplemented with 10% dimethyl sulfoxide (Merck, Darmstadt, Germany) and 20% fetal calf serum (FCS; Gibco) and stored in liquid nitrogen. On the day of the experiments, BM cells were thawed. Cells were washed and resuspended in DMEM supplemented with 10% FCS. Before RNA and DNA isolation, cells were washed with phosphate-buffered saline (Gibco).
###end p 11
###begin title 12
MDR1, MRP1, LRP, and BCRP mRNA analysis
###end title 12
###begin p 13
###xml 90 92 90 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 570 574 549 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 576 580 555 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRP1</italic>
###xml 582 585 561 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRP</italic>
###xml 591 595 570 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
The drug resistance proteins were analyzed using the methods that we previously reported [11]. In brief, total RNA was isolated using the TRISOLVtrade mark extraction as described by the manufacturer (Biotecx, Houston, TX). RNA was aliquoted and stored at -80degreesC. RNA samples were analyzed for RNA integrity by gel electrophoresis. cDNA was synthesized by the use of the TaqMan Reverse Transcription Reagents (Applied Biosystems, Foster City, CA), diluted, aliquoted, and stored at -80degreesC. Quantitative RT-PCR was used to measure the mRNA expression levels of MDR1, MRP1, LRP, and BCRP by Taqman-chemistry on an ABI PRISM 7700 sequence detector (Applied Biosystems) using two endogenous reference genes, i.e., glyceraldehyde-3-phosphate dehydrogenase and porphobilinogen deaminase.
###end p 13
###begin title 14
Definition of endpoints
###end title 14
###begin p 15
###xml 53 55 53 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 335 343 <span type="species:ncbi:9606">Patients</span>
###xml 596 604 <span type="species:ncbi:9606">Patients</span>
###xml 739 747 <span type="species:ncbi:9606">patients</span>
###xml 952 960 <span type="species:ncbi:9606">Patients</span>
The clinical endpoints have been defined previously [14]. In brief, complete response (CR) was defined as a normocellular BM with <5% blasts, no Auer rods, and no evidence of extramedullary involvement. Because data on peripheral blood recovery within 60 days were not always available, they were not considered as a criterium for CR. Patients who relapsed or died within 28 days after CR were considered as not having achieved a CR. Event-free survival (EFS) was calculated from the date of randomization until no CR on induction therapy, relapse after CR, or death in CR, whichever came first. Patients who did not reach CR were considered failure for EFS at 1 day after randomization. Disease-free survival (DFS) was determined for all patients who achieved CR on induction therapy and was calculated from the date of CR until relapse or death, whichever came first. Overall survival (OS) was measured from randomization until death from any cause. Patients who were still alive at the date of last contact were then censored.
###end p 15
###begin title 16
Statistical analysis
###end title 16
###begin p 17
###xml 204 209 204 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#945;</italic>
###xml 244 252 <span type="species:ncbi:9606">patients</span>
The original phase 3 trial had been designed to detect with a power of 80% an increase in 2-year EFS from 9.5% in the control arm (without PSC-833) to 18% in the PSC-833 arm (two-sided significance level alpha = 0.05) and included 419 eligible patients.
###end p 17
###begin p 18
###xml 161 165 161 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 167 171 167 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRP1</italic>
###xml 173 176 173 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRP</italic>
###xml 182 186 182 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 45 53 <span type="species:ncbi:9606">patients</span>
mRNA data were obtained from a subset of 154 patients with sufficient BM samples in our tissue bank available for analysis. Baseline parameters of interest were MDR1, MRP1, LRP, and BCRP mRNA expression. Clinical endpoints were CR rate, EFS, DFS, and OS.
###end p 18
###begin p 19
###xml 141 144 141 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#967;</italic>
###xml 144 145 142 143 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 383 386 381 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#967;</italic>
###xml 386 387 382 383 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 561 563 557 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 587 591 583 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 593 597 589 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRP1</italic>
###xml 599 602 595 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRP</italic>
###xml 608 612 604 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 676 678 672 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 937 941 933 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 946 950 942 946 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 1007 1011 1003 1007 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 1012 1016 1008 1012 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 1059 1061 1055 1057 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 1310 1314 1306 1310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 1319 1323 1315 1319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 1573 1574 1569 1570 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1839 1841 1835 1837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 1924 1926 1920 1922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 1942 1943 1938 1939 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 2080 2081 2076 2077 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 28 36 <span type="species:ncbi:9606">patients</span>
###xml 292 299 <span type="species:ncbi:9606">patient</span>
###xml 907 915 <span type="species:ncbi:9606">patients</span>
###xml 1066 1074 <span type="species:ncbi:9606">patients</span>
###xml 1121 1129 <span type="species:ncbi:9606">patients</span>
###xml 1276 1284 <span type="species:ncbi:9606">patients</span>
###xml 1735 1743 <span type="species:ncbi:9606">patients</span>
Baseline characteristics of patients with or without mRNA expression data available were compared using the Fisher exact test or the Pearson chi2 test in case of discrete variables, whichever appropriate, or the Wilcoxon rank-sum test in case of continuous variables. The association between patient baseline characteristics and mRNA expression levels was analyzed using the Pearson chi2 test of the Spearman rank correlation test, whichever was appropriate. The prognostic value of mRNA levels with respect to CR rate was determined using logistic regression [17] whereas the impact of MDR1, MRP1, LRP, and BCRP on EFS, DFS, and OS was analyzed with Cox regression analysis [18]. For this purpose, the natural logarithm of the mRNA expression levels of the four resistance genes were included in the analyses because of the very skewed distribution of the original mRNA levels. In addition, the outcome of patients with coexpression of MDR1 and BCRP was evaluated to confirm the poor prognosis of AML with MDR1/BCRP coexpression reported by Benderra et al. [19] in patients with a median age of 45 years or older. These patients were defined as having mRNA levels of these two drug resistance genes equal to or higher than the median. Their outcome was compared to the other patients with at least one of the MDR1 and BCRP mRNA expression levels below the median. Logistic regression and Cox regression analyses were performed unadjusted, as well as adjusted for other prognostic factors, i.e., secondary AML, natural logarithm of WBC count, square root of percentage CD34+ cells, and cytogenetic risk (favorable/intermediate versus unfavorable versus unknown), as well as for treatment arm in the phase 3 trial, as about half of the patients had been randomized to receive PSC-833 in addition to their chemotherapy. Kaplan-Meier curves [20] were generated to illustrate survival and were compared using the log-rank test [21]. All reported p values are two-sided and, in view of the exploratory nature of these analyses, were calculated without adjustment for multiple testing. p values </= 0.05 were considered statistically significant.
###end p 19
###begin title 20
Results
###end title 20
###begin p 21
###xml 301 302 301 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 337 338 337 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 371 372 371 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 407 408 407 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 418 420 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 47 55 <span type="species:ncbi:9606">patients</span>
###xml 527 535 <span type="species:ncbi:9606">patients</span>
In the phase 3 trial, a total of 419 untreated patients with AML aged 60 years and older were randomized to receive two induction cycles with or without PSC-833. As reported, no difference was found between both treatment arms as regards CR rate (54% in the PSC-833 arm versus 48% in the control arm, p = 0.22), 5-year EFS (7 versus 8%, p = 0.53) nor DFS (13 versus 17%, p = 0.06) and OS (10% in both arms, p = 0.52) [14]. We previously reported the role of functional MDR1 expression with respect to clinical outcome in these patients.
###end p 21
###begin p 22
###xml 152 156 152 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 158 162 158 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRP1</italic>
###xml 164 167 164 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRP</italic>
###xml 173 177 173 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 316 317 316 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 501 502 501 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 565 569 565 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 571 575 571 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRP1</italic>
###xml 577 580 577 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRP</italic>
###xml 586 590 586 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 739 740 739 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 832 833 832 833 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 875 876 875 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 906 913 906 913 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 913 1015 913 1015 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="23">Comparison between patients with or without data available for expression of the drug resistance genes</p>
###xml 913 1015 913 1015 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="23">Comparison between patients with or without data available for expression of the drug resistance genes</p></caption>
###xml 1015 1016 1015 1016 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">&#160;</th>
###xml 1016 1047 1016 1047 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="2">Drug resistance genes evaluated</th>
###xml 1047 1048 1047 1048 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="2">&#160;</th>
###xml 1015 1048 1015 1048 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th rowspan="2">&#160;</th><th colspan="2">Drug resistance genes evaluated</th><th colspan="2">&#160;</th></tr>
###xml 1052 1053 1052 1053 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 1048 1057 1048 1057 <th xmlns:xlink="http://www.w3.org/1999/xlink">Yes <italic>N</italic> (%)</th>
###xml 1060 1061 1060 1061 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 1057 1065 1057 1065 <th xmlns:xlink="http://www.w3.org/1999/xlink">No <italic>N</italic> (%)</th>
###xml 1071 1072 1071 1072 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 1065 1076 1065 1076 <th xmlns:xlink="http://www.w3.org/1999/xlink">Total <italic>N</italic> (%)</th>
###xml 1076 1077 1076 1077 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1076 1077 1076 1077 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>p</italic></th>
###xml 1048 1077 1048 1077 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>Yes <italic>N</italic> (%)</th><th>No <italic>N</italic> (%)</th><th>Total <italic>N</italic> (%)</th><th><italic>p</italic></th></tr>
###xml 1015 1077 1015 1077 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th rowspan="2">&#160;</th><th colspan="2">Drug resistance genes evaluated</th><th colspan="2">&#160;</th></tr><tr><th>Yes <italic>N</italic> (%)</th><th>No <italic>N</italic> (%)</th><th>Total <italic>N</italic> (%)</th><th><italic>p</italic></th></tr></thead>
###xml 1077 1095 1077 1095 <td xmlns:xlink="http://www.w3.org/1999/xlink">Number of patients</td>
###xml 1095 1098 1095 1098 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">154</td>
###xml 1098 1101 1098 1101 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">265</td>
###xml 1101 1104 1101 1104 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">419</td>
###xml 1104 1104 1104 1104 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1077 1104 1077 1104 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Number of patients</td><td align="left">154</td><td align="left">265</td><td align="left">419</td><td/></tr>
###xml 1104 1127 1104 1127 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="5">Patient characteristics</td>
###xml 1104 1127 1104 1127 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="5">Patient characteristics</td></tr>
###xml 1127 1146 1127 1146 <td xmlns:xlink="http://www.w3.org/1999/xlink">Median age, (range)</td>
###xml 1146 1156 1146 1156 <td xmlns:xlink="http://www.w3.org/1999/xlink">67 (60&#8211;85)</td>
###xml 1156 1166 1156 1166 <td xmlns:xlink="http://www.w3.org/1999/xlink">68 (58&#8211;85)</td>
###xml 1166 1176 1166 1176 <td xmlns:xlink="http://www.w3.org/1999/xlink">67 (58&#8211;85)</td>
###xml 1176 1180 1176 1180 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.52</td>
###xml 1127 1180 1127 1180 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Median age, (range)</td><td>67 (60&#8211;85)</td><td>68 (58&#8211;85)</td><td>67 (58&#8211;85)</td><td align="left">0.52</td></tr>
###xml 1180 1183 1180 1183 <td xmlns:xlink="http://www.w3.org/1999/xlink">Sex</td>
###xml 1183 1183 1183 1183 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1183 1183 1183 1183 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1183 1183 1183 1183 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1183 1187 1183 1187 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.26</td>
###xml 1180 1187 1180 1187 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Sex</td><td/><td/><td/><td align="left">0.26</td></tr>
###xml 1187 1192 1187 1192 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;Male</td>
###xml 1192 1199 1192 1199 <td xmlns:xlink="http://www.w3.org/1999/xlink">86 (56)</td>
###xml 1199 1207 1199 1207 <td xmlns:xlink="http://www.w3.org/1999/xlink">163 (62)</td>
###xml 1207 1215 1207 1215 <td xmlns:xlink="http://www.w3.org/1999/xlink">249 (59)</td>
###xml 1215 1215 1215 1215 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1187 1215 1187 1215 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;Male</td><td>86 (56)</td><td>163 (62)</td><td>249 (59)</td><td/></tr>
###xml 1215 1222 1215 1222 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;Female</td>
###xml 1222 1229 1222 1229 <td xmlns:xlink="http://www.w3.org/1999/xlink">68 (44)</td>
###xml 1229 1237 1229 1237 <td xmlns:xlink="http://www.w3.org/1999/xlink">102 (38)</td>
###xml 1237 1245 1237 1245 <td xmlns:xlink="http://www.w3.org/1999/xlink">170 (41)</td>
###xml 1245 1245 1245 1245 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1215 1245 1215 1245 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;Female</td><td>68 (44)</td><td>102 (38)</td><td>170 (41)</td><td/></tr>
###xml 1245 1258 1245 1258 <td xmlns:xlink="http://www.w3.org/1999/xlink">Secondary AML</td>
###xml 1258 1265 1258 1265 <td xmlns:xlink="http://www.w3.org/1999/xlink">31 (20)</td>
###xml 1265 1272 1265 1272 <td xmlns:xlink="http://www.w3.org/1999/xlink">73 (28)</td>
###xml 1272 1280 1272 1280 <td xmlns:xlink="http://www.w3.org/1999/xlink">104 (25)</td>
###xml 1280 1284 1280 1284 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.09</td>
###xml 1245 1284 1245 1284 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Secondary AML</td><td>31 (20)</td><td>73 (28)</td><td>104 (25)</td><td align="left">0.09</td></tr>
###xml 1305 1306 1305 1306 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 1284 1316 1284 1316 <td xmlns:xlink="http://www.w3.org/1999/xlink">Median WBC count (&#215;10<sup>9</sup>/l; range)</td>
###xml 1316 1330 1316 1330 <td xmlns:xlink="http://www.w3.org/1999/xlink">19.1 (0.1&#8211;389)</td>
###xml 1330 1343 1330 1343 <td xmlns:xlink="http://www.w3.org/1999/xlink">5.6 (0.5&#8211;300)</td>
###xml 1343 1356 1343 1356 <td xmlns:xlink="http://www.w3.org/1999/xlink">8.9 (0.1&#8211;389)</td>
###xml 1356 1361 1356 1361 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.001</td>
###xml 1284 1361 1284 1361 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Median WBC count (&#215;10<sup>9</sup>/l; range)</td><td>19.1 (0.1&#8211;389)</td><td>5.6 (0.5&#8211;300)</td><td>8.9 (0.1&#8211;389)</td><td align="left">0.001</td></tr>
###xml 1361 1362 1361 1362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 1361 1362 1361 1362 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>N</italic></td>
###xml 1362 1365 1362 1365 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">146</td>
###xml 1365 1368 1365 1368 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">243</td>
###xml 1368 1371 1368 1371 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">389</td>
###xml 1371 1371 1371 1371 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1361 1371 1361 1371 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>N</italic></td><td align="left">146</td><td align="left">243</td><td align="left">389</td><td/></tr>
###xml 1384 1385 1384 1385 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1371 1394 1371 1394 <td xmlns:xlink="http://www.w3.org/1999/xlink">Median % CD34<sup>+</sup>, (range)</td>
###xml 1394 1409 1394 1409 <td xmlns:xlink="http://www.w3.org/1999/xlink">32.5 (0.1&#8211;97.9)</td>
###xml 1409 1424 1409 1424 <td xmlns:xlink="http://www.w3.org/1999/xlink">29.7 (0.1&#8211;93.7)</td>
###xml 1424 1439 1424 1439 <td xmlns:xlink="http://www.w3.org/1999/xlink">30.3 (0.1&#8211;97.9)</td>
###xml 1439 1443 1439 1443 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.50</td>
###xml 1371 1443 1371 1443 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Median % CD34<sup>+</sup>, (range)</td><td>32.5 (0.1&#8211;97.9)</td><td>29.7 (0.1&#8211;93.7)</td><td>30.3 (0.1&#8211;97.9)</td><td align="left">0.50</td></tr>
###xml 1443 1444 1443 1444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 1443 1444 1443 1444 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>N</italic></td>
###xml 1444 1447 1444 1447 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">152</td>
###xml 1447 1450 1447 1450 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">157</td>
###xml 1450 1453 1450 1453 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">309</td>
###xml 1453 1453 1453 1453 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1443 1453 1443 1453 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>N</italic></td><td align="left">152</td><td align="left">157</td><td align="left">309</td><td/></tr>
###xml 1484 1485 1484 1485 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1453 1485 1453 1485 <td xmlns:xlink="http://www.w3.org/1999/xlink">Cytogenetic risk classification<sup>a</sup></td>
###xml 1485 1485 1485 1485 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1485 1485 1485 1485 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1485 1485 1485 1485 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1485 1489 1485 1489 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.12</td>
###xml 1453 1489 1453 1489 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Cytogenetic risk classification<sup>a</sup></td><td/><td/><td/><td align="left">0.12</td></tr>
###xml 1489 1499 1489 1499 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;Favorable</td>
###xml 1499 1504 1499 1504 <td xmlns:xlink="http://www.w3.org/1999/xlink">3 (3)</td>
###xml 1504 1509 1504 1509 <td xmlns:xlink="http://www.w3.org/1999/xlink">2 (1)</td>
###xml 1509 1514 1509 1514 <td xmlns:xlink="http://www.w3.org/1999/xlink">5 (2)</td>
###xml 1514 1514 1514 1514 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1489 1514 1489 1514 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;Favorable</td><td>3 (3)</td><td>2 (1)</td><td>5 (2)</td><td/></tr>
###xml 1514 1527 1514 1527 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;Intermediate</td>
###xml 1527 1534 1527 1534 <td xmlns:xlink="http://www.w3.org/1999/xlink">90 (80)</td>
###xml 1534 1542 1534 1542 <td xmlns:xlink="http://www.w3.org/1999/xlink">132 (73)</td>
###xml 1542 1550 1542 1550 <td xmlns:xlink="http://www.w3.org/1999/xlink">222 (76)</td>
###xml 1550 1550 1550 1550 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1514 1550 1514 1550 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;Intermediate</td><td>90 (80)</td><td>132 (73)</td><td>222 (76)</td><td/></tr>
###xml 1550 1562 1550 1562 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;Unfavorable</td>
###xml 1562 1569 1562 1569 <td xmlns:xlink="http://www.w3.org/1999/xlink">19 (17)</td>
###xml 1569 1576 1569 1576 <td xmlns:xlink="http://www.w3.org/1999/xlink">47 (26)</td>
###xml 1576 1583 1576 1583 <td xmlns:xlink="http://www.w3.org/1999/xlink">66 (23)</td>
###xml 1583 1583 1583 1583 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1550 1583 1550 1583 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;Unfavorable</td><td>19 (17)</td><td>47 (26)</td><td>66 (23)</td><td/></tr>
###xml 1583 1591 1583 1591 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;No data</td>
###xml 1591 1600 1591 1600 <td xmlns:xlink="http://www.w3.org/1999/xlink">42 (n.i.)</td>
###xml 1600 1609 1600 1609 <td xmlns:xlink="http://www.w3.org/1999/xlink">84 (n.i.)</td>
###xml 1609 1619 1609 1619 <td xmlns:xlink="http://www.w3.org/1999/xlink">126 (n.i.)</td>
###xml 1619 1619 1619 1619 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1583 1619 1583 1619 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;No data</td><td>42 (n.i.)</td><td>84 (n.i.)</td><td>126 (n.i.)</td><td/></tr>
###xml 1619 1643 1619 1643 <td xmlns:xlink="http://www.w3.org/1999/xlink">Treatment arm randomized</td>
###xml 1643 1643 1643 1643 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1643 1643 1643 1643 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1643 1643 1643 1643 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1643 1647 1643 1647 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.02</td>
###xml 1619 1647 1619 1647 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Treatment arm randomized</td><td/><td/><td/><td align="left">0.02</td></tr>
###xml 1647 1657 1647 1657 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;DNR/ara-C</td>
###xml 1657 1664 1657 1664 <td xmlns:xlink="http://www.w3.org/1999/xlink">66 (43)</td>
###xml 1664 1672 1664 1672 <td xmlns:xlink="http://www.w3.org/1999/xlink">145 (55)</td>
###xml 1672 1680 1672 1680 <td xmlns:xlink="http://www.w3.org/1999/xlink">211 (50)</td>
###xml 1680 1680 1680 1680 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1647 1680 1647 1680 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;DNR/ara-C</td><td>66 (43)</td><td>145 (55)</td><td>211 (50)</td><td/></tr>
###xml 1680 1699 1680 1699 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;DNR/ara-C +PSC-833</td>
###xml 1699 1706 1699 1706 <td xmlns:xlink="http://www.w3.org/1999/xlink">88 (57)</td>
###xml 1706 1714 1706 1714 <td xmlns:xlink="http://www.w3.org/1999/xlink">120 (45)</td>
###xml 1714 1722 1714 1722 <td xmlns:xlink="http://www.w3.org/1999/xlink">208 (50)</td>
###xml 1722 1722 1722 1722 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1680 1722 1680 1722 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;DNR/ara-C +PSC-833</td><td>88 (57)</td><td>120 (45)</td><td>208 (50)</td><td/></tr>
###xml 1722 1739 1722 1739 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="5">Treatment outcome</td>
###xml 1722 1739 1722 1739 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="5">Treatment outcome</td></tr>
###xml 1739 1758 1739 1758 <td xmlns:xlink="http://www.w3.org/1999/xlink">CR rate, % (95% CI)</td>
###xml 1758 1768 1758 1768 <td xmlns:xlink="http://www.w3.org/1999/xlink">52 (44&#8211;60)</td>
###xml 1768 1778 1768 1778 <td xmlns:xlink="http://www.w3.org/1999/xlink">50 (44&#8211;56)</td>
###xml 1778 1788 1778 1788 <td xmlns:xlink="http://www.w3.org/1999/xlink">51 (46&#8211;56)</td>
###xml 1788 1792 1788 1792 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.73</td>
###xml 1739 1792 1739 1792 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>CR rate, % (95% CI)</td><td>52 (44&#8211;60)</td><td>50 (44&#8211;56)</td><td>51 (46&#8211;56)</td><td align="left">0.73</td></tr>
###xml 1792 1807 1792 1807 <td xmlns:xlink="http://www.w3.org/1999/xlink">EFS, % (95% CI)</td>
###xml 1807 1807 1807 1807 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1807 1807 1807 1807 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1807 1807 1807 1807 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1807 1811 1807 1811 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.72</td>
###xml 1792 1811 1792 1811 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>EFS, % (95% CI)</td><td/><td/><td/><td align="left">0.72</td></tr>
###xml 1811 1818 1811 1818 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;1&#160;year</td>
###xml 1818 1828 1818 1828 <td xmlns:xlink="http://www.w3.org/1999/xlink">23 (17&#8211;30)</td>
###xml 1828 1838 1828 1838 <td xmlns:xlink="http://www.w3.org/1999/xlink">23 (18&#8211;28)</td>
###xml 1838 1848 1838 1848 <td xmlns:xlink="http://www.w3.org/1999/xlink">23 (19&#8211;27)</td>
###xml 1848 1848 1848 1848 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1811 1848 1811 1848 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;1&#160;year</td><td>23 (17&#8211;30)</td><td>23 (18&#8211;28)</td><td>23 (19&#8211;27)</td><td/></tr>
###xml 1848 1856 1848 1856 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;5&#160;years</td>
###xml 1856 1864 1856 1864 <td xmlns:xlink="http://www.w3.org/1999/xlink">9 (5&#8211;14)</td>
###xml 1864 1872 1864 1872 <td xmlns:xlink="http://www.w3.org/1999/xlink">7 (4&#8211;11)</td>
###xml 1872 1880 1872 1880 <td xmlns:xlink="http://www.w3.org/1999/xlink">8 (5&#8211;11)</td>
###xml 1880 1880 1880 1880 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1848 1880 1848 1880 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;5&#160;years</td><td>9 (5&#8211;14)</td><td>7 (4&#8211;11)</td><td>8 (5&#8211;11)</td><td/></tr>
###xml 1880 1895 1880 1895 <td xmlns:xlink="http://www.w3.org/1999/xlink">DFS, % (95% CI)</td>
###xml 1895 1895 1895 1895 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1895 1895 1895 1895 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1895 1895 1895 1895 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1895 1899 1895 1899 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.81</td>
###xml 1880 1899 1880 1899 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>DFS, % (95% CI)</td><td/><td/><td/><td align="left">0.81</td></tr>
###xml 1899 1906 1899 1906 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;1&#160;year</td>
###xml 1906 1916 1906 1916 <td xmlns:xlink="http://www.w3.org/1999/xlink">38 (27&#8211;48)</td>
###xml 1916 1926 1916 1926 <td xmlns:xlink="http://www.w3.org/1999/xlink">39 (31&#8211;48)</td>
###xml 1926 1936 1926 1936 <td xmlns:xlink="http://www.w3.org/1999/xlink">39 (32&#8211;45)</td>
###xml 1936 1936 1936 1936 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1899 1936 1899 1936 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;1&#160;year</td><td>38 (27&#8211;48)</td><td>39 (31&#8211;48)</td><td>39 (32&#8211;45)</td><td/></tr>
###xml 1936 1944 1936 1944 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;5&#160;years</td>
###xml 1944 1954 1944 1954 <td xmlns:xlink="http://www.w3.org/1999/xlink">17 (10&#8211;26)</td>
###xml 1954 1963 1954 1963 <td xmlns:xlink="http://www.w3.org/1999/xlink">14 (9&#8211;21)</td>
###xml 1963 1973 1963 1973 <td xmlns:xlink="http://www.w3.org/1999/xlink">15 (11&#8211;21)</td>
###xml 1973 1973 1973 1973 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1936 1973 1936 1973 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;5&#160;years</td><td>17 (10&#8211;26)</td><td>14 (9&#8211;21)</td><td>15 (11&#8211;21)</td><td/></tr>
###xml 1973 1987 1973 1987 <td xmlns:xlink="http://www.w3.org/1999/xlink">OS, % (95% CI)</td>
###xml 1987 1987 1987 1987 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1987 1987 1987 1987 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1987 1987 1987 1987 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1987 1991 1987 1991 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.31</td>
###xml 1973 1991 1973 1991 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>OS, % (95% CI)</td><td/><td/><td/><td align="left">0.31</td></tr>
###xml 1991 1998 1991 1998 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;1&#160;year</td>
###xml 1998 2008 1998 2008 <td xmlns:xlink="http://www.w3.org/1999/xlink">42 (34&#8211;50)</td>
###xml 2008 2018 2008 2018 <td xmlns:xlink="http://www.w3.org/1999/xlink">41 (35&#8211;46)</td>
###xml 2018 2028 2018 2028 <td xmlns:xlink="http://www.w3.org/1999/xlink">41 (36&#8211;46)</td>
###xml 2028 2028 2028 2028 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1991 2028 1991 2028 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;1&#160;year</td><td>42 (34&#8211;50)</td><td>41 (35&#8211;46)</td><td>41 (36&#8211;46)</td><td/></tr>
###xml 2028 2036 2028 2036 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;5&#160;years</td>
###xml 2036 2045 2036 2045 <td xmlns:xlink="http://www.w3.org/1999/xlink">14 (9&#8211;20)</td>
###xml 2045 2053 2045 2053 <td xmlns:xlink="http://www.w3.org/1999/xlink">8 (5&#8211;12)</td>
###xml 2053 2062 2053 2062 <td xmlns:xlink="http://www.w3.org/1999/xlink">10 (7&#8211;14)</td>
###xml 2062 2062 2062 2062 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2028 2062 2028 2062 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;5&#160;years</td><td>14 (9&#8211;20)</td><td>8 (5&#8211;12)</td><td>10 (7&#8211;14)</td><td/></tr>
###xml 1077 2062 1077 2062 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>Number of patients</td><td align="left">154</td><td align="left">265</td><td align="left">419</td><td/></tr><tr><td colspan="5">Patient characteristics</td></tr><tr><td>Median age, (range)</td><td>67 (60&#8211;85)</td><td>68 (58&#8211;85)</td><td>67 (58&#8211;85)</td><td align="left">0.52</td></tr><tr><td>Sex</td><td/><td/><td/><td align="left">0.26</td></tr><tr><td>&#160;Male</td><td>86 (56)</td><td>163 (62)</td><td>249 (59)</td><td/></tr><tr><td>&#160;Female</td><td>68 (44)</td><td>102 (38)</td><td>170 (41)</td><td/></tr><tr><td>Secondary AML</td><td>31 (20)</td><td>73 (28)</td><td>104 (25)</td><td align="left">0.09</td></tr><tr><td>Median WBC count (&#215;10<sup>9</sup>/l; range)</td><td>19.1 (0.1&#8211;389)</td><td>5.6 (0.5&#8211;300)</td><td>8.9 (0.1&#8211;389)</td><td align="left">0.001</td></tr><tr><td><italic>N</italic></td><td align="left">146</td><td align="left">243</td><td align="left">389</td><td/></tr><tr><td>Median % CD34<sup>+</sup>, (range)</td><td>32.5 (0.1&#8211;97.9)</td><td>29.7 (0.1&#8211;93.7)</td><td>30.3 (0.1&#8211;97.9)</td><td align="left">0.50</td></tr><tr><td><italic>N</italic></td><td align="left">152</td><td align="left">157</td><td align="left">309</td><td/></tr><tr><td>Cytogenetic risk classification<sup>a</sup></td><td/><td/><td/><td align="left">0.12</td></tr><tr><td>&#160;Favorable</td><td>3 (3)</td><td>2 (1)</td><td>5 (2)</td><td/></tr><tr><td>&#160;Intermediate</td><td>90 (80)</td><td>132 (73)</td><td>222 (76)</td><td/></tr><tr><td>&#160;Unfavorable</td><td>19 (17)</td><td>47 (26)</td><td>66 (23)</td><td/></tr><tr><td>&#160;No data</td><td>42 (n.i.)</td><td>84 (n.i.)</td><td>126 (n.i.)</td><td/></tr><tr><td>Treatment arm randomized</td><td/><td/><td/><td align="left">0.02</td></tr><tr><td>&#160;DNR/ara-C</td><td>66 (43)</td><td>145 (55)</td><td>211 (50)</td><td/></tr><tr><td>&#160;DNR/ara-C +PSC-833</td><td>88 (57)</td><td>120 (45)</td><td>208 (50)</td><td/></tr><tr><td colspan="5">Treatment outcome</td></tr><tr><td>CR rate, % (95% CI)</td><td>52 (44&#8211;60)</td><td>50 (44&#8211;56)</td><td>51 (46&#8211;56)</td><td align="left">0.73</td></tr><tr><td>EFS, % (95% CI)</td><td/><td/><td/><td align="left">0.72</td></tr><tr><td>&#160;1&#160;year</td><td>23 (17&#8211;30)</td><td>23 (18&#8211;28)</td><td>23 (19&#8211;27)</td><td/></tr><tr><td>&#160;5&#160;years</td><td>9 (5&#8211;14)</td><td>7 (4&#8211;11)</td><td>8 (5&#8211;11)</td><td/></tr><tr><td>DFS, % (95% CI)</td><td/><td/><td/><td align="left">0.81</td></tr><tr><td>&#160;1&#160;year</td><td>38 (27&#8211;48)</td><td>39 (31&#8211;48)</td><td>39 (32&#8211;45)</td><td/></tr><tr><td>&#160;5&#160;years</td><td>17 (10&#8211;26)</td><td>14 (9&#8211;21)</td><td>15 (11&#8211;21)</td><td/></tr><tr><td>OS, % (95% CI)</td><td/><td/><td/><td align="left">0.31</td></tr><tr><td>&#160;1&#160;year</td><td>42 (34&#8211;50)</td><td>41 (35&#8211;46)</td><td>41 (36&#8211;46)</td><td/></tr><tr><td>&#160;5&#160;years</td><td>14 (9&#8211;20)</td><td>8 (5&#8211;12)</td><td>10 (7&#8211;14)</td><td/></tr></tbody>
###xml 1015 2062 1015 2062 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th rowspan="2">&#160;</th><th colspan="2">Drug resistance genes evaluated</th><th colspan="2">&#160;</th></tr><tr><th>Yes <italic>N</italic> (%)</th><th>No <italic>N</italic> (%)</th><th>Total <italic>N</italic> (%)</th><th><italic>p</italic></th></tr></thead><tbody><tr><td>Number of patients</td><td align="left">154</td><td align="left">265</td><td align="left">419</td><td/></tr><tr><td colspan="5">Patient characteristics</td></tr><tr><td>Median age, (range)</td><td>67 (60&#8211;85)</td><td>68 (58&#8211;85)</td><td>67 (58&#8211;85)</td><td align="left">0.52</td></tr><tr><td>Sex</td><td/><td/><td/><td align="left">0.26</td></tr><tr><td>&#160;Male</td><td>86 (56)</td><td>163 (62)</td><td>249 (59)</td><td/></tr><tr><td>&#160;Female</td><td>68 (44)</td><td>102 (38)</td><td>170 (41)</td><td/></tr><tr><td>Secondary AML</td><td>31 (20)</td><td>73 (28)</td><td>104 (25)</td><td align="left">0.09</td></tr><tr><td>Median WBC count (&#215;10<sup>9</sup>/l; range)</td><td>19.1 (0.1&#8211;389)</td><td>5.6 (0.5&#8211;300)</td><td>8.9 (0.1&#8211;389)</td><td align="left">0.001</td></tr><tr><td><italic>N</italic></td><td align="left">146</td><td align="left">243</td><td align="left">389</td><td/></tr><tr><td>Median % CD34<sup>+</sup>, (range)</td><td>32.5 (0.1&#8211;97.9)</td><td>29.7 (0.1&#8211;93.7)</td><td>30.3 (0.1&#8211;97.9)</td><td align="left">0.50</td></tr><tr><td><italic>N</italic></td><td align="left">152</td><td align="left">157</td><td align="left">309</td><td/></tr><tr><td>Cytogenetic risk classification<sup>a</sup></td><td/><td/><td/><td align="left">0.12</td></tr><tr><td>&#160;Favorable</td><td>3 (3)</td><td>2 (1)</td><td>5 (2)</td><td/></tr><tr><td>&#160;Intermediate</td><td>90 (80)</td><td>132 (73)</td><td>222 (76)</td><td/></tr><tr><td>&#160;Unfavorable</td><td>19 (17)</td><td>47 (26)</td><td>66 (23)</td><td/></tr><tr><td>&#160;No data</td><td>42 (n.i.)</td><td>84 (n.i.)</td><td>126 (n.i.)</td><td/></tr><tr><td>Treatment arm randomized</td><td/><td/><td/><td align="left">0.02</td></tr><tr><td>&#160;DNR/ara-C</td><td>66 (43)</td><td>145 (55)</td><td>211 (50)</td><td/></tr><tr><td>&#160;DNR/ara-C +PSC-833</td><td>88 (57)</td><td>120 (45)</td><td>208 (50)</td><td/></tr><tr><td colspan="5">Treatment outcome</td></tr><tr><td>CR rate, % (95% CI)</td><td>52 (44&#8211;60)</td><td>50 (44&#8211;56)</td><td>51 (46&#8211;56)</td><td align="left">0.73</td></tr><tr><td>EFS, % (95% CI)</td><td/><td/><td/><td align="left">0.72</td></tr><tr><td>&#160;1&#160;year</td><td>23 (17&#8211;30)</td><td>23 (18&#8211;28)</td><td>23 (19&#8211;27)</td><td/></tr><tr><td>&#160;5&#160;years</td><td>9 (5&#8211;14)</td><td>7 (4&#8211;11)</td><td>8 (5&#8211;11)</td><td/></tr><tr><td>DFS, % (95% CI)</td><td/><td/><td/><td align="left">0.81</td></tr><tr><td>&#160;1&#160;year</td><td>38 (27&#8211;48)</td><td>39 (31&#8211;48)</td><td>39 (32&#8211;45)</td><td/></tr><tr><td>&#160;5&#160;years</td><td>17 (10&#8211;26)</td><td>14 (9&#8211;21)</td><td>15 (11&#8211;21)</td><td/></tr><tr><td>OS, % (95% CI)</td><td/><td/><td/><td align="left">0.31</td></tr><tr><td>&#160;1&#160;year</td><td>42 (34&#8211;50)</td><td>41 (35&#8211;46)</td><td>41 (36&#8211;46)</td><td/></tr><tr><td>&#160;5&#160;years</td><td>14 (9&#8211;20)</td><td>8 (5&#8211;12)</td><td>10 (7&#8211;14)</td><td/></tr></tbody></table>
###xml 2062 2162 2062 2162 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="24">The results indicate that, apart from WBC count, there are no differences between the two subgroups.</p>
###xml 2162 2163 2162 2163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 2230 2234 2230 2234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n.i.</italic>
###xml 2162 2276 2162 2276 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="25"><italic>N</italic> number of patients with data (if not available for all patients); <italic>n.i.</italic> not included when calculating percentages</p>
###xml 2276 2277 2276 2277 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 2853 2855 2853 2855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 2276 2857 2276 2857 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="26"><sup>a</sup>Classification of cytogenetic abnormalities only for 293 patients with successful cytogenetics. Favorable risk: t(8;21), inv(16) or t(16;16). Unfavorable risk: the presence of monosomies or deletions of chromosomes 5 or 7, abnormalities of the long arm of chromosome 3(q21;q26), t(6;9), abnormalities involving the long arm of chromosome 11 (11q23), or complex cytogenetic abnormalities (defined as at least three unrelated cytogenetic abnormalities in one clone). Patients who did not meet the criteria for favorable or unfavorable risk were classified as intermediate risk [<xref ref-type="bibr" rid="CR14">14</xref>].</p>
###xml 2062 2857 2062 2857 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="24">The results indicate that, apart from WBC count, there are no differences between the two subgroups.</p><p textid="25"><italic>N</italic> number of patients with data (if not available for all patients); <italic>n.i.</italic> not included when calculating percentages</p><p textid="26"><sup>a</sup>Classification of cytogenetic abnormalities only for 293 patients with successful cytogenetics. Favorable risk: t(8;21), inv(16) or t(16;16). Unfavorable risk: the presence of monosomies or deletions of chromosomes 5 or 7, abnormalities of the long arm of chromosome 3(q21;q26), t(6;9), abnormalities involving the long arm of chromosome 11 (11q23), or complex cytogenetic abnormalities (defined as at least three unrelated cytogenetic abnormalities in one clone). Patients who did not meet the criteria for favorable or unfavorable risk were classified as intermediate risk [<xref ref-type="bibr" rid="CR14">14</xref>].</p></table-wrap-foot>
###xml 906 2857 906 2857 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="23">Comparison between patients with or without data available for expression of the drug resistance genes</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">&#160;</th><th colspan="2">Drug resistance genes evaluated</th><th colspan="2">&#160;</th></tr><tr><th>Yes <italic>N</italic> (%)</th><th>No <italic>N</italic> (%)</th><th>Total <italic>N</italic> (%)</th><th><italic>p</italic></th></tr></thead><tbody><tr><td>Number of patients</td><td align="left">154</td><td align="left">265</td><td align="left">419</td><td/></tr><tr><td colspan="5">Patient characteristics</td></tr><tr><td>Median age, (range)</td><td>67 (60&#8211;85)</td><td>68 (58&#8211;85)</td><td>67 (58&#8211;85)</td><td align="left">0.52</td></tr><tr><td>Sex</td><td/><td/><td/><td align="left">0.26</td></tr><tr><td>&#160;Male</td><td>86 (56)</td><td>163 (62)</td><td>249 (59)</td><td/></tr><tr><td>&#160;Female</td><td>68 (44)</td><td>102 (38)</td><td>170 (41)</td><td/></tr><tr><td>Secondary AML</td><td>31 (20)</td><td>73 (28)</td><td>104 (25)</td><td align="left">0.09</td></tr><tr><td>Median WBC count (&#215;10<sup>9</sup>/l; range)</td><td>19.1 (0.1&#8211;389)</td><td>5.6 (0.5&#8211;300)</td><td>8.9 (0.1&#8211;389)</td><td align="left">0.001</td></tr><tr><td><italic>N</italic></td><td align="left">146</td><td align="left">243</td><td align="left">389</td><td/></tr><tr><td>Median % CD34<sup>+</sup>, (range)</td><td>32.5 (0.1&#8211;97.9)</td><td>29.7 (0.1&#8211;93.7)</td><td>30.3 (0.1&#8211;97.9)</td><td align="left">0.50</td></tr><tr><td><italic>N</italic></td><td align="left">152</td><td align="left">157</td><td align="left">309</td><td/></tr><tr><td>Cytogenetic risk classification<sup>a</sup></td><td/><td/><td/><td align="left">0.12</td></tr><tr><td>&#160;Favorable</td><td>3 (3)</td><td>2 (1)</td><td>5 (2)</td><td/></tr><tr><td>&#160;Intermediate</td><td>90 (80)</td><td>132 (73)</td><td>222 (76)</td><td/></tr><tr><td>&#160;Unfavorable</td><td>19 (17)</td><td>47 (26)</td><td>66 (23)</td><td/></tr><tr><td>&#160;No data</td><td>42 (n.i.)</td><td>84 (n.i.)</td><td>126 (n.i.)</td><td/></tr><tr><td>Treatment arm randomized</td><td/><td/><td/><td align="left">0.02</td></tr><tr><td>&#160;DNR/ara-C</td><td>66 (43)</td><td>145 (55)</td><td>211 (50)</td><td/></tr><tr><td>&#160;DNR/ara-C +PSC-833</td><td>88 (57)</td><td>120 (45)</td><td>208 (50)</td><td/></tr><tr><td colspan="5">Treatment outcome</td></tr><tr><td>CR rate, % (95% CI)</td><td>52 (44&#8211;60)</td><td>50 (44&#8211;56)</td><td>51 (46&#8211;56)</td><td align="left">0.73</td></tr><tr><td>EFS, % (95% CI)</td><td/><td/><td/><td align="left">0.72</td></tr><tr><td>&#160;1&#160;year</td><td>23 (17&#8211;30)</td><td>23 (18&#8211;28)</td><td>23 (19&#8211;27)</td><td/></tr><tr><td>&#160;5&#160;years</td><td>9 (5&#8211;14)</td><td>7 (4&#8211;11)</td><td>8 (5&#8211;11)</td><td/></tr><tr><td>DFS, % (95% CI)</td><td/><td/><td/><td align="left">0.81</td></tr><tr><td>&#160;1&#160;year</td><td>38 (27&#8211;48)</td><td>39 (31&#8211;48)</td><td>39 (32&#8211;45)</td><td/></tr><tr><td>&#160;5&#160;years</td><td>17 (10&#8211;26)</td><td>14 (9&#8211;21)</td><td>15 (11&#8211;21)</td><td/></tr><tr><td>OS, % (95% CI)</td><td/><td/><td/><td align="left">0.31</td></tr><tr><td>&#160;1&#160;year</td><td>42 (34&#8211;50)</td><td>41 (35&#8211;46)</td><td>41 (36&#8211;46)</td><td/></tr><tr><td>&#160;5&#160;years</td><td>14 (9&#8211;20)</td><td>8 (5&#8211;12)</td><td>10 (7&#8211;14)</td><td/></tr></tbody></table><table-wrap-foot><p textid="24">The results indicate that, apart from WBC count, there are no differences between the two subgroups.</p><p textid="25"><italic>N</italic> number of patients with data (if not available for all patients); <italic>n.i.</italic> not included when calculating percentages</p><p textid="26"><sup>a</sup>Classification of cytogenetic abnormalities only for 293 patients with successful cytogenetics. Favorable risk: t(8;21), inv(16) or t(16;16). Unfavorable risk: the presence of monosomies or deletions of chromosomes 5 or 7, abnormalities of the long arm of chromosome 3(q21;q26), t(6;9), abnormalities involving the long arm of chromosome 11 (11q23), or complex cytogenetic abnormalities (defined as at least three unrelated cytogenetic abnormalities in one clone). Patients who did not meet the criteria for favorable or unfavorable risk were classified as intermediate risk [<xref ref-type="bibr" rid="CR14">14</xref>].</p></table-wrap-foot></table-wrap>
###xml 18 26 <span type="species:ncbi:9606">patients</span>
###xml 407 415 <span type="species:ncbi:9606">patients</span>
###xml 437 445 <span type="species:ncbi:9606">patients</span>
###xml 717 724 <span type="species:ncbi:9606">patient</span>
###xml 752 760 <span type="species:ncbi:9606">patients</span>
###xml 896 904 <span type="species:ncbi:9606">patients</span>
###xml 932 940 <span type="species:ncbi:9606">patients</span>
###xml 2174 2182 <span type="species:ncbi:9606">patients</span>
###xml 2219 2227 <span type="species:ncbi:9606">patients</span>
###xml 2334 2342 <span type="species:ncbi:9606">patients</span>
###xml 2742 2750 <span type="species:ncbi:9606">Patients</span>
In 154/419 of the patients, sufficient BM cells were available in our tissue bank to investigate the mRNA expression level of the drug resistance genes MDR1, MRP1, LRP, and BCRP. This subgroup consisted of a representative group according to age, gender, CD34 expression, cytogenetics, and FAB classification (Table 1). In this test group, a higher WBC count at diagnosis was observed than in the other 265 patients, and relatively more patients had been randomized to the PSC-833 arm (57 versus 45%, p = 0.02). There was no significant difference in the levels of MDR1, MRP1, LRP, nor BCRP mRNA expression between the two treatment arms (data not shown). The CR rate and survival endpoints were also similar in both patient groups (Table 1). However, patients with mRNA data in the PSC-833 arm had a higher CR rate (61 versus 40%, p = 0.02), whereas this was 54 versus 48% (p = 0.22) in all 419 patients. Table 1Comparison between patients with or without data available for expression of the drug resistance genes Drug resistance genes evaluated Yes N (%)No N (%)Total N (%)pNumber of patients154265419Patient characteristicsMedian age, (range)67 (60-85)68 (58-85)67 (58-85)0.52Sex0.26 Male86 (56)163 (62)249 (59) Female68 (44)102 (38)170 (41)Secondary AML31 (20)73 (28)104 (25)0.09Median WBC count (x109/l; range)19.1 (0.1-389)5.6 (0.5-300)8.9 (0.1-389)0.001N146243389Median % CD34+, (range)32.5 (0.1-97.9)29.7 (0.1-93.7)30.3 (0.1-97.9)0.50N152157309Cytogenetic risk classificationa0.12 Favorable3 (3)2 (1)5 (2) Intermediate90 (80)132 (73)222 (76) Unfavorable19 (17)47 (26)66 (23) No data42 (n.i.)84 (n.i.)126 (n.i.)Treatment arm randomized0.02 DNR/ara-C66 (43)145 (55)211 (50) DNR/ara-C +PSC-83388 (57)120 (45)208 (50)Treatment outcomeCR rate, % (95% CI)52 (44-60)50 (44-56)51 (46-56)0.73EFS, % (95% CI)0.72 1 year23 (17-30)23 (18-28)23 (19-27) 5 years9 (5-14)7 (4-11)8 (5-11)DFS, % (95% CI)0.81 1 year38 (27-48)39 (31-48)39 (32-45) 5 years17 (10-26)14 (9-21)15 (11-21)OS, % (95% CI)0.31 1 year42 (34-50)41 (35-46)41 (36-46) 5 years14 (9-20)8 (5-12)10 (7-14)The results indicate that, apart from WBC count, there are no differences between the two subgroups.N number of patients with data (if not available for all patients); n.i. not included when calculating percentagesaClassification of cytogenetic abnormalities only for 293 patients with successful cytogenetics. Favorable risk: t(8;21), inv(16) or t(16;16). Unfavorable risk: the presence of monosomies or deletions of chromosomes 5 or 7, abnormalities of the long arm of chromosome 3(q21;q26), t(6;9), abnormalities involving the long arm of chromosome 11 (11q23), or complex cytogenetic abnormalities (defined as at least three unrelated cytogenetic abnormalities in one clone). Patients who did not meet the criteria for favorable or unfavorable risk were classified as intermediate risk [14].
###end p 22
###begin p 23
###xml 19 27 <span type="species:ncbi:9606">patients</span>
Comparison between patients with or without data available for expression of the drug resistance genes
###end p 23
###begin p 24
The results indicate that, apart from WBC count, there are no differences between the two subgroups.
###end p 24
###begin p 25
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 68 72 68 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n.i.</italic>
###xml 12 20 <span type="species:ncbi:9606">patients</span>
###xml 57 65 <span type="species:ncbi:9606">patients</span>
N number of patients with data (if not available for all patients); n.i. not included when calculating percentages
###end p 25
###begin p 26
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 577 579 577 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 58 66 <span type="species:ncbi:9606">patients</span>
###xml 466 474 <span type="species:ncbi:9606">Patients</span>
aClassification of cytogenetic abnormalities only for 293 patients with successful cytogenetics. Favorable risk: t(8;21), inv(16) or t(16;16). Unfavorable risk: the presence of monosomies or deletions of chromosomes 5 or 7, abnormalities of the long arm of chromosome 3(q21;q26), t(6;9), abnormalities involving the long arm of chromosome 11 (11q23), or complex cytogenetic abnormalities (defined as at least three unrelated cytogenetic abnormalities in one clone). Patients who did not meet the criteria for favorable or unfavorable risk were classified as intermediate risk [14].
###end p 26
###begin p 27
###xml 121 122 121 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 125 129 125 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRP1</italic>
###xml 134 137 134 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRP</italic>
###xml 227 231 227 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 236 240 236 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 333 337 333 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 352 356 352 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 419 423 419 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRP1</italic>
###xml 428 431 428 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRP</italic>
###xml 460 461 460 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 540 544 540 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 546 547 546 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 566 570 566 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRP1</italic>
###xml 575 578 575 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRP</italic>
###xml 592 593 592 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 608 609 608 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 736 740 736 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 788 789 788 789 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 830 832 830 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 835 842 835 842 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 957 961 957 961 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 962 966 962 966 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 842 979 842 979 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="28">Association between clinical patient characteristics and the mRNA expression of the four drug resistance genes and <italic>MDR1</italic>/<italic>BCRP</italic> coexpression</p>
###xml 842 979 842 979 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="28">Association between clinical patient characteristics and the mRNA expression of the four drug resistance genes and <italic>MDR1</italic>/<italic>BCRP</italic> coexpression</p></caption>
###xml 979 980 979 980 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">&#160;</th>
###xml 980 998 980 998 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="5">mRNA expression of</th>
###xml 979 998 979 998 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th rowspan="2">&#160;</th><th colspan="5">mRNA expression of</th></tr>
###xml 998 1002 998 1002 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 998 1002 998 1002 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>MDR1</italic></th>
###xml 1002 1006 1002 1006 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRP1</italic>
###xml 1002 1006 1002 1006 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>MRP1</italic></th>
###xml 1006 1009 1006 1009 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRP</italic>
###xml 1006 1009 1006 1009 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LRP</italic></th>
###xml 1009 1013 1009 1013 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 1009 1013 1009 1013 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>BCRP</italic></th>
###xml 1013 1017 1013 1017 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 1018 1022 1018 1022 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 1013 1035 1013 1035 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>MDR1</italic>/<italic>BCRP</italic> coexpression</th>
###xml 998 1035 998 1035 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th><italic>MDR1</italic></th><th><italic>MRP1</italic></th><th><italic>LRP</italic></th><th><italic>BCRP</italic></th><th><italic>MDR1</italic>/<italic>BCRP</italic> coexpression</th></tr>
###xml 979 1035 979 1035 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th rowspan="2">&#160;</th><th colspan="5">mRNA expression of</th></tr><tr><th><italic>MDR1</italic></th><th><italic>MRP1</italic></th><th><italic>LRP</italic></th><th><italic>BCRP</italic></th><th><italic>MDR1</italic>/<italic>BCRP</italic> coexpression</th></tr></thead>
###xml 1035 1049 1035 1049 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="6">Characteristic</td>
###xml 1035 1049 1035 1049 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="6">Characteristic</td></tr>
###xml 1049 1053 1049 1053 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">&#160;Age</td>
###xml 1053 1057 1053 1057 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.15</td>
###xml 1057 1062 1057 1062 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;0.01</td>
###xml 1062 1067 1062 1067 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;0.09</td>
###xml 1067 1071 1067 1071 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.09</td>
###xml 1071 1075 1071 1075 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.07</td>
###xml 1049 1075 1049 1075 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="2">&#160;Age</td><td>0.15</td><td>&#8722;0.01</td><td>&#8722;0.09</td><td>0.09</td><td>0.07</td></tr>
###xml 1075 1080 1075 1080 <td xmlns:xlink="http://www.w3.org/1999/xlink">(153)</td>
###xml 1080 1085 1080 1085 <td xmlns:xlink="http://www.w3.org/1999/xlink">(153)</td>
###xml 1085 1090 1085 1090 <td xmlns:xlink="http://www.w3.org/1999/xlink">(153)</td>
###xml 1090 1095 1090 1095 <td xmlns:xlink="http://www.w3.org/1999/xlink">(137)</td>
###xml 1095 1100 1095 1100 <td xmlns:xlink="http://www.w3.org/1999/xlink">(147)</td>
###xml 1075 1100 1075 1100 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>(153)</td><td>(153)</td><td>(153)</td><td>(137)</td><td>(147)</td></tr>
###xml 1100 1114 1100 1114 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">&#160;Secondary AML</td>
###xml 1114 1118 1114 1118 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.06</td>
###xml 1118 1125 1118 1125 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;0.22**</td>
###xml 1125 1132 1125 1132 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;0.21**</td>
###xml 1132 1137 1132 1137 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.19*</td>
###xml 1137 1141 1137 1141 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.12</td>
###xml 1100 1141 1100 1141 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="2">&#160;Secondary AML</td><td>0.06</td><td>&#8722;0.22**</td><td>&#8722;0.21**</td><td>0.19*</td><td>0.12</td></tr>
###xml 1141 1146 1141 1146 <td xmlns:xlink="http://www.w3.org/1999/xlink">(153)</td>
###xml 1146 1151 1146 1151 <td xmlns:xlink="http://www.w3.org/1999/xlink">(153)</td>
###xml 1151 1156 1151 1156 <td xmlns:xlink="http://www.w3.org/1999/xlink">(153)</td>
###xml 1156 1161 1156 1161 <td xmlns:xlink="http://www.w3.org/1999/xlink">(137)</td>
###xml 1161 1166 1161 1166 <td xmlns:xlink="http://www.w3.org/1999/xlink">(147)</td>
###xml 1141 1166 1141 1166 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>(153)</td><td>(153)</td><td>(153)</td><td>(137)</td><td>(147)</td></tr>
###xml 1166 1176 1166 1176 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">&#160;WBC count</td>
###xml 1176 1182 1176 1182 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;0.17*</td>
###xml 1182 1189 1182 1189 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.28***</td>
###xml 1189 1196 1189 1196 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.36***</td>
###xml 1196 1204 1196 1204 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;0.36***</td>
###xml 1204 1212 1204 1212 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;0.35***</td>
###xml 1166 1212 1166 1212 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="2">&#160;WBC count</td><td>&#8722;0.17*</td><td>0.28***</td><td>0.36***</td><td>&#8722;0.36***</td><td>&#8722;0.35***</td></tr>
###xml 1212 1217 1212 1217 <td xmlns:xlink="http://www.w3.org/1999/xlink">(145)</td>
###xml 1217 1222 1217 1222 <td xmlns:xlink="http://www.w3.org/1999/xlink">(145)</td>
###xml 1222 1227 1222 1227 <td xmlns:xlink="http://www.w3.org/1999/xlink">(145)</td>
###xml 1227 1232 1227 1232 <td xmlns:xlink="http://www.w3.org/1999/xlink">(131)</td>
###xml 1232 1237 1232 1237 <td xmlns:xlink="http://www.w3.org/1999/xlink">(139)</td>
###xml 1212 1237 1212 1237 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>(145)</td><td>(145)</td><td>(145)</td><td>(131)</td><td>(139)</td></tr>
###xml 1242 1243 1242 1243 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1237 1243 1237 1243 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">&#160;CD34<sup>+</sup></td>
###xml 1243 1250 1243 1250 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.54***</td>
###xml 1250 1254 1250 1254 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.14</td>
###xml 1254 1259 1254 1259 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;0.08</td>
###xml 1259 1264 1259 1264 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.17*</td>
###xml 1264 1270 1264 1270 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.27**</td>
###xml 1237 1270 1237 1270 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="2">&#160;CD34<sup>+</sup></td><td>0.54***</td><td>0.14</td><td>&#8722;0.08</td><td>0.17*</td><td>0.27**</td></tr>
###xml 1270 1275 1270 1275 <td xmlns:xlink="http://www.w3.org/1999/xlink">(151)</td>
###xml 1275 1280 1275 1280 <td xmlns:xlink="http://www.w3.org/1999/xlink">(151)</td>
###xml 1280 1285 1280 1285 <td xmlns:xlink="http://www.w3.org/1999/xlink">(151)</td>
###xml 1285 1290 1285 1290 <td xmlns:xlink="http://www.w3.org/1999/xlink">(135)</td>
###xml 1290 1295 1290 1295 <td xmlns:xlink="http://www.w3.org/1999/xlink">(145)</td>
###xml 1270 1295 1270 1295 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>(151)</td><td>(151)</td><td>(151)</td><td>(135)</td><td>(145)</td></tr>
###xml 1295 1308 1295 1308 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;Unfavorable </td>
###xml 1308 1312 1308 1312 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.11</td>
###xml 1312 1317 1312 1317 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;0.05</td>
###xml 1317 1323 1317 1323 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;0.23*</td>
###xml 1323 1327 1323 1327 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.13</td>
###xml 1327 1331 1327 1331 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.10</td>
###xml 1295 1331 1295 1331 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;Unfavorable </td><td>0.11</td><td>&#8722;0.05</td><td>&#8722;0.23*</td><td>0.13</td><td>0.10</td></tr>
###xml 1331 1348 1331 1348 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;Cytogenetic risk</td>
###xml 1348 1353 1348 1353 <td xmlns:xlink="http://www.w3.org/1999/xlink">(111)</td>
###xml 1353 1358 1353 1358 <td xmlns:xlink="http://www.w3.org/1999/xlink">(111)</td>
###xml 1358 1363 1358 1363 <td xmlns:xlink="http://www.w3.org/1999/xlink">(111)</td>
###xml 1363 1367 1363 1367 <td xmlns:xlink="http://www.w3.org/1999/xlink">(98)</td>
###xml 1367 1372 1367 1372 <td xmlns:xlink="http://www.w3.org/1999/xlink">(106)</td>
###xml 1331 1372 1331 1372 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;Cytogenetic risk</td><td>(111)</td><td>(111)</td><td>(111)</td><td>(98)</td><td>(106)</td></tr>
###xml 1035 1372 1035 1372 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td colspan="6">Characteristic</td></tr><tr><td rowspan="2">&#160;Age</td><td>0.15</td><td>&#8722;0.01</td><td>&#8722;0.09</td><td>0.09</td><td>0.07</td></tr><tr><td>(153)</td><td>(153)</td><td>(153)</td><td>(137)</td><td>(147)</td></tr><tr><td rowspan="2">&#160;Secondary AML</td><td>0.06</td><td>&#8722;0.22**</td><td>&#8722;0.21**</td><td>0.19*</td><td>0.12</td></tr><tr><td>(153)</td><td>(153)</td><td>(153)</td><td>(137)</td><td>(147)</td></tr><tr><td rowspan="2">&#160;WBC count</td><td>&#8722;0.17*</td><td>0.28***</td><td>0.36***</td><td>&#8722;0.36***</td><td>&#8722;0.35***</td></tr><tr><td>(145)</td><td>(145)</td><td>(145)</td><td>(131)</td><td>(139)</td></tr><tr><td rowspan="2">&#160;CD34<sup>+</sup></td><td>0.54***</td><td>0.14</td><td>&#8722;0.08</td><td>0.17*</td><td>0.27**</td></tr><tr><td>(151)</td><td>(151)</td><td>(151)</td><td>(135)</td><td>(145)</td></tr><tr><td>&#160;Unfavorable </td><td>0.11</td><td>&#8722;0.05</td><td>&#8722;0.23*</td><td>0.13</td><td>0.10</td></tr><tr><td>&#160;Cytogenetic risk</td><td>(111)</td><td>(111)</td><td>(111)</td><td>(98)</td><td>(106)</td></tr></tbody>
###xml 979 1372 979 1372 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th rowspan="2">&#160;</th><th colspan="5">mRNA expression of</th></tr><tr><th><italic>MDR1</italic></th><th><italic>MRP1</italic></th><th><italic>LRP</italic></th><th><italic>BCRP</italic></th><th><italic>MDR1</italic>/<italic>BCRP</italic> coexpression</th></tr></thead><tbody><tr><td colspan="6">Characteristic</td></tr><tr><td rowspan="2">&#160;Age</td><td>0.15</td><td>&#8722;0.01</td><td>&#8722;0.09</td><td>0.09</td><td>0.07</td></tr><tr><td>(153)</td><td>(153)</td><td>(153)</td><td>(137)</td><td>(147)</td></tr><tr><td rowspan="2">&#160;Secondary AML</td><td>0.06</td><td>&#8722;0.22**</td><td>&#8722;0.21**</td><td>0.19*</td><td>0.12</td></tr><tr><td>(153)</td><td>(153)</td><td>(153)</td><td>(137)</td><td>(147)</td></tr><tr><td rowspan="2">&#160;WBC count</td><td>&#8722;0.17*</td><td>0.28***</td><td>0.36***</td><td>&#8722;0.36***</td><td>&#8722;0.35***</td></tr><tr><td>(145)</td><td>(145)</td><td>(145)</td><td>(131)</td><td>(139)</td></tr><tr><td rowspan="2">&#160;CD34<sup>+</sup></td><td>0.54***</td><td>0.14</td><td>&#8722;0.08</td><td>0.17*</td><td>0.27**</td></tr><tr><td>(151)</td><td>(151)</td><td>(151)</td><td>(135)</td><td>(145)</td></tr><tr><td>&#160;Unfavorable </td><td>0.11</td><td>&#8722;0.05</td><td>&#8722;0.23*</td><td>0.13</td><td>0.10</td></tr><tr><td>&#160;Cytogenetic risk</td><td>(111)</td><td>(111)</td><td>(111)</td><td>(98)</td><td>(106)</td></tr></tbody></table>
###xml 1372 1718 1372 1718 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="29">Unfavorable cytogenetic risk was defined by the presence of monosomies or deletions of chromosomes 5 or 7, abnormalities of the long arm of chromosome 3(q21;q6), t(6;9), abnormalities involving the long arm of chromosome 11 (11q23), or complex cytogenetic abnormalities (defined as at least three unrelated cytogenetic abnormalities in one clone)</p>
###xml 1718 1877 1718 1877 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="30">Each cell displays the Spearman rank correlation coefficient between two variables and, between brackets, the number of patients with both variables available.</p>
###xml 1878 1879 1878 1879 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1890 1891 1890 1891 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1903 1904 1903 1904 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1877 1912 1877 1912 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="31">*<italic>p</italic>&#8201;&lt;&#8201;0.05; **<italic>p</italic>&#8201;&lt;&#8201;0.01; ***<italic>p</italic>&#8201;&lt;&#8201;0.001</p>
###xml 1372 1912 1372 1912 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="29">Unfavorable cytogenetic risk was defined by the presence of monosomies or deletions of chromosomes 5 or 7, abnormalities of the long arm of chromosome 3(q21;q6), t(6;9), abnormalities involving the long arm of chromosome 11 (11q23), or complex cytogenetic abnormalities (defined as at least three unrelated cytogenetic abnormalities in one clone)</p><p textid="30">Each cell displays the Spearman rank correlation coefficient between two variables and, between brackets, the number of patients with both variables available.</p><p textid="31">*<italic>p</italic>&#8201;&lt;&#8201;0.05; **<italic>p</italic>&#8201;&lt;&#8201;0.01; ***<italic>p</italic>&#8201;&lt;&#8201;0.001</p></table-wrap-foot>
###xml 835 1912 835 1912 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="28">Association between clinical patient characteristics and the mRNA expression of the four drug resistance genes and <italic>MDR1</italic>/<italic>BCRP</italic> coexpression</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">&#160;</th><th colspan="5">mRNA expression of</th></tr><tr><th><italic>MDR1</italic></th><th><italic>MRP1</italic></th><th><italic>LRP</italic></th><th><italic>BCRP</italic></th><th><italic>MDR1</italic>/<italic>BCRP</italic> coexpression</th></tr></thead><tbody><tr><td colspan="6">Characteristic</td></tr><tr><td rowspan="2">&#160;Age</td><td>0.15</td><td>&#8722;0.01</td><td>&#8722;0.09</td><td>0.09</td><td>0.07</td></tr><tr><td>(153)</td><td>(153)</td><td>(153)</td><td>(137)</td><td>(147)</td></tr><tr><td rowspan="2">&#160;Secondary AML</td><td>0.06</td><td>&#8722;0.22**</td><td>&#8722;0.21**</td><td>0.19*</td><td>0.12</td></tr><tr><td>(153)</td><td>(153)</td><td>(153)</td><td>(137)</td><td>(147)</td></tr><tr><td rowspan="2">&#160;WBC count</td><td>&#8722;0.17*</td><td>0.28***</td><td>0.36***</td><td>&#8722;0.36***</td><td>&#8722;0.35***</td></tr><tr><td>(145)</td><td>(145)</td><td>(145)</td><td>(131)</td><td>(139)</td></tr><tr><td rowspan="2">&#160;CD34<sup>+</sup></td><td>0.54***</td><td>0.14</td><td>&#8722;0.08</td><td>0.17*</td><td>0.27**</td></tr><tr><td>(151)</td><td>(151)</td><td>(151)</td><td>(135)</td><td>(145)</td></tr><tr><td>&#160;Unfavorable </td><td>0.11</td><td>&#8722;0.05</td><td>&#8722;0.23*</td><td>0.13</td><td>0.10</td></tr><tr><td>&#160;Cytogenetic risk</td><td>(111)</td><td>(111)</td><td>(111)</td><td>(98)</td><td>(106)</td></tr></tbody></table><table-wrap-foot><p textid="29">Unfavorable cytogenetic risk was defined by the presence of monosomies or deletions of chromosomes 5 or 7, abnormalities of the long arm of chromosome 3(q21;q6), t(6;9), abnormalities involving the long arm of chromosome 11 (11q23), or complex cytogenetic abnormalities (defined as at least three unrelated cytogenetic abnormalities in one clone)</p><p textid="30">Each cell displays the Spearman rank correlation coefficient between two variables and, between brackets, the number of patients with both variables available.</p><p textid="31">*<italic>p</italic>&#8201;&lt;&#8201;0.05; **<italic>p</italic>&#8201;&lt;&#8201;0.01; ***<italic>p</italic>&#8201;&lt;&#8201;0.001</p></table-wrap-foot></table-wrap>
###xml 105 113 <span type="species:ncbi:9606">patients</span>
###xml 640 648 <span type="species:ncbi:9606">patients</span>
###xml 871 878 <span type="species:ncbi:9606">patient</span>
###xml 1838 1846 <span type="species:ncbi:9606">patients</span>
The mRNA expression levels of the resistance genes were not significantly associated with the age of the patients (Table 2). MRP1 and LRP expression showed a strong positive correlation with WBC count. Negative associations of MDR1 and BCRP with WBC count were observed. A significant positive association was found between CD34 and MDR1 and also with BCRP mRNA expression. No significant correlation was found between MRP1 nor LRP, and CD34 expression (Table 2). Interestingly, secondary AML cases had a significantly higher expression of BCRP (p < 0.05) and lower MRP1 and LRP levels (both p < 0.01, Table 2). In the vast majority of our patients, also P-gp efflux and expression data were available. Function and expression data and MDR1 mRNA expression levels were highly correlated (p < 0.001), which was published recently [22]. Table 2Association between clinical patient characteristics and the mRNA expression of the four drug resistance genes and MDR1/BCRP coexpression mRNA expression ofMDR1MRP1LRPBCRPMDR1/BCRP coexpressionCharacteristic Age0.15-0.01-0.090.090.07(153)(153)(153)(137)(147) Secondary AML0.06-0.22**-0.21**0.19*0.12(153)(153)(153)(137)(147) WBC count-0.17*0.28***0.36***-0.36***-0.35***(145)(145)(145)(131)(139) CD34+0.54***0.14-0.080.17*0.27**(151)(151)(151)(135)(145) Unfavorable 0.11-0.05-0.23*0.130.10 Cytogenetic risk(111)(111)(111)(98)(106)Unfavorable cytogenetic risk was defined by the presence of monosomies or deletions of chromosomes 5 or 7, abnormalities of the long arm of chromosome 3(q21;q6), t(6;9), abnormalities involving the long arm of chromosome 11 (11q23), or complex cytogenetic abnormalities (defined as at least three unrelated cytogenetic abnormalities in one clone)Each cell displays the Spearman rank correlation coefficient between two variables and, between brackets, the number of patients with both variables available.*p < 0.05; **p < 0.01; ***p < 0.001
###end p 27
###begin p 28
###xml 115 119 115 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 120 124 120 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 29 36 <span type="species:ncbi:9606">patient</span>
Association between clinical patient characteristics and the mRNA expression of the four drug resistance genes and MDR1/BCRP coexpression
###end p 28
###begin p 29
Unfavorable cytogenetic risk was defined by the presence of monosomies or deletions of chromosomes 5 or 7, abnormalities of the long arm of chromosome 3(q21;q6), t(6;9), abnormalities involving the long arm of chromosome 11 (11q23), or complex cytogenetic abnormalities (defined as at least three unrelated cytogenetic abnormalities in one clone)
###end p 29
###begin p 30
###xml 120 128 <span type="species:ncbi:9606">patients</span>
Each cell displays the Spearman rank correlation coefficient between two variables and, between brackets, the number of patients with both variables available.
###end p 30
###begin p 31
###xml 1 2 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 13 14 13 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 26 27 26 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
*p < 0.05; **p < 0.01; ***p < 0.001
###end p 31
###begin p 32
###xml 51 55 51 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 60 64 60 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 89 90 89 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 114 118 114 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRP1</italic>
###xml 123 126 123 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRP</italic>
###xml 133 134 133 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 149 150 149 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 194 198 194 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 203 207 203 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRP1</italic>
###xml 220 224 220 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 229 232 229 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRP</italic>
###xml 239 240 239 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 255 256 255 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 296 300 296 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 305 309 305 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 415 416 415 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 478 479 478 479 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 512 513 512 513 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 517 518 517 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 559 563 559 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 565 569 565 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 590 594 590 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 599 603 599 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 645 646 645 646 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 660 661 660 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 664 670 664 670 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 690 694 690 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 696 700 696 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRP1</italic>
###xml 702 705 702 705 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRP</italic>
###xml 711 715 711 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 745 748 745 748 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dot</italic>
###xml 912 913 912 913 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 930 931 930 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink">x</italic>
###xml 937 938 937 938 <italic xmlns:xlink="http://www.w3.org/1999/xlink">y</italic>
###xml 974 975 974 975 <italic xmlns:xlink="http://www.w3.org/1999/xlink">X</italic>
###xml 1033 1034 1033 1034 <italic xmlns:xlink="http://www.w3.org/1999/xlink">X</italic>
###xml 1055 1056 1055 1056 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 1101 1102 1101 1102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1104 1105 1104 1105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1173 1177 1173 1177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 1182 1186 1182 1186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 1225 1226 1225 1226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1275 1279 1275 1279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRP1</italic>
###xml 1284 1287 1284 1287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRP</italic>
###xml 1311 1315 1311 1315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 1350 1354 1350 1354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRP1</italic>
###xml 1359 1362 1359 1362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRP</italic>
###xml 670 1362 670 1362 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="33">Association between <italic>MDR1</italic>, <italic>MRP1</italic>, <italic>LRP</italic>, and <italic>BCRP</italic> mRNA expression levels. Each <italic>dot</italic> represents the expression of two drug resistance genes in one patient. The Spearman rank correlation coefficient has been calculated, along with the corresponding <italic>p</italic> value. Both the <italic>x</italic>- and <italic>y</italic>-axis have a logarithmic scale trim(<italic>X</italic>)* indicates that the 2.5% smallest and largest values of <italic>X</italic> have been shrinked; <italic>r</italic>, Spearman rank correlation coefficient; and <italic>p</italic>, <italic>p</italic> value. The results show a significant positive correlation between <italic>MDR1</italic> and <italic>BCRP</italic> mRNA expression as illustrated by the <italic>p</italic> value and correlation coefficient. In addition, <italic>MRP1</italic> and <italic>LRP</italic> are highly associated. <italic>BCRP</italic> shows a negative correlation with <italic>MRP1</italic> and <italic>LRP</italic></p>
###xml 670 1362 670 1362 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="33">Association between <italic>MDR1</italic>, <italic>MRP1</italic>, <italic>LRP</italic>, and <italic>BCRP</italic> mRNA expression levels. Each <italic>dot</italic> represents the expression of two drug resistance genes in one patient. The Spearman rank correlation coefficient has been calculated, along with the corresponding <italic>p</italic> value. Both the <italic>x</italic>- and <italic>y</italic>-axis have a logarithmic scale trim(<italic>X</italic>)* indicates that the 2.5% smallest and largest values of <italic>X</italic> have been shrinked; <italic>r</italic>, Spearman rank correlation coefficient; and <italic>p</italic>, <italic>p</italic> value. The results show a significant positive correlation between <italic>MDR1</italic> and <italic>BCRP</italic> mRNA expression as illustrated by the <italic>p</italic> value and correlation coefficient. In addition, <italic>MRP1</italic> and <italic>LRP</italic> are highly associated. <italic>BCRP</italic> shows a negative correlation with <italic>MRP1</italic> and <italic>LRP</italic></p></caption>
###xml 1362 1362 1362 1362 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="277_2007_269_Fig1_HTML" id="MO1"/>
###xml 664 1362 664 1362 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="33">Association between <italic>MDR1</italic>, <italic>MRP1</italic>, <italic>LRP</italic>, and <italic>BCRP</italic> mRNA expression levels. Each <italic>dot</italic> represents the expression of two drug resistance genes in one patient. The Spearman rank correlation coefficient has been calculated, along with the corresponding <italic>p</italic> value. Both the <italic>x</italic>- and <italic>y</italic>-axis have a logarithmic scale trim(<italic>X</italic>)* indicates that the 2.5% smallest and largest values of <italic>X</italic> have been shrinked; <italic>r</italic>, Spearman rank correlation coefficient; and <italic>p</italic>, <italic>p</italic> value. The results show a significant positive correlation between <italic>MDR1</italic> and <italic>BCRP</italic> mRNA expression as illustrated by the <italic>p</italic> value and correlation coefficient. In addition, <italic>MRP1</italic> and <italic>LRP</italic> are highly associated. <italic>BCRP</italic> shows a negative correlation with <italic>MRP1</italic> and <italic>LRP</italic></p></caption><graphic position="anchor" xlink:href="277_2007_269_Fig1_HTML" id="MO1"/></fig>
###xml 18 26 <span type="species:ncbi:9606">patients</span>
###xml 266 274 <span type="species:ncbi:9606">patients</span>
###xml 811 818 <span type="species:ncbi:9606">patient</span>
In this cohort of patients of higher age with AML, MDR1 and BCRP were highly associated (p < 0.001), just as were MRP1 and LRP mRNA (p < 0.001; Fig. 1). A negative association was found between BCRP and MRP1 and between BCRP and LRP (both p < 0.001; Fig. 1). The 40 patients with coexpression of BCRP and MDR1 had significantly higher CD34 expression (median 39.5% [range 0.1-97.7%] versus 25.9% [range 0.1-97.9%]; p = 0.001) and a lower WBC count (median 4.5 [range 0.8-300]x109/l versus 28.1 [range 0.1-389]x109/l; p < 0.001). No significant correlation of MDR1, BCRP, or coexpression of MDR1 and BCRP was found with unfavorable cytogenetics (p = 0.4; Table 2). Fig. 1Association between MDR1, MRP1, LRP, and BCRP mRNA expression levels. Each dot represents the expression of two drug resistance genes in one patient. The Spearman rank correlation coefficient has been calculated, along with the corresponding p value. Both the x- and y-axis have a logarithmic scale trim(X)* indicates that the 2.5% smallest and largest values of X have been shrinked; r, Spearman rank correlation coefficient; and p, p value. The results show a significant positive correlation between MDR1 and BCRP mRNA expression as illustrated by the p value and correlation coefficient. In addition, MRP1 and LRP are highly associated. BCRP shows a negative correlation with MRP1 and LRP
###end p 32
###begin p 33
###xml 20 24 20 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 26 30 26 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRP1</italic>
###xml 32 35 32 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRP</italic>
###xml 41 45 41 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 75 78 75 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dot</italic>
###xml 242 243 242 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 260 261 260 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">x</italic>
###xml 267 268 267 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">y</italic>
###xml 304 305 304 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">X</italic>
###xml 363 364 363 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">X</italic>
###xml 385 386 385 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 431 432 431 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 434 435 434 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 503 507 503 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 512 516 512 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 555 556 555 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 605 609 605 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRP1</italic>
###xml 614 617 614 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRP</italic>
###xml 641 645 641 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 680 684 680 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRP1</italic>
###xml 689 692 689 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRP</italic>
###xml 141 148 <span type="species:ncbi:9606">patient</span>
Association between MDR1, MRP1, LRP, and BCRP mRNA expression levels. Each dot represents the expression of two drug resistance genes in one patient. The Spearman rank correlation coefficient has been calculated, along with the corresponding p value. Both the x- and y-axis have a logarithmic scale trim(X)* indicates that the 2.5% smallest and largest values of X have been shrinked; r, Spearman rank correlation coefficient; and p, p value. The results show a significant positive correlation between MDR1 and BCRP mRNA expression as illustrated by the p value and correlation coefficient. In addition, MRP1 and LRP are highly associated. BCRP shows a negative correlation with MRP1 and LRP
###end p 33
###begin p 34
###xml 297 301 297 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 353 357 353 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 422 423 422 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 442 446 442 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRP1</italic>
###xml 448 451 448 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRP</italic>
###xml 457 461 457 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 501 502 501 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 505 509 505 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 563 567 563 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 612 613 612 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 634 638 634 638 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 670 671 670 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 721 725 721 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 726 730 726 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 751 752 751 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 759 760 759 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 863 883 863 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Sec7" ref-type="sec">Statistical analysis</xref>
###xml 891 895 891 895 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 896 900 896 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 1004 1005 1004 1005 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1065 1066 1065 1066 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 1210 1211 1210 1211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1269 1270 1269 1270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1315 1316 1315 1316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1366 1367 1366 1367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1378 1385 1378 1385 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;3</label>
###xml 1385 1477 1385 1477 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="35">Prognostic value of drug resistance gene expression w.r.t. CR rate, EFS, DFS from CR, and OS</p>
###xml 1385 1477 1385 1477 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="35">Prognostic value of drug resistance gene expression w.r.t. CR rate, EFS, DFS from CR, and OS</p></caption>
###xml 1477 1478 1477 1478 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">&#160;</th>
###xml 1478 1485 1478 1485 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="3">CR rate</th>
###xml 1485 1488 1485 1488 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="3">EFS</th>
###xml 1488 1491 1488 1491 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="3">DFS</th>
###xml 1491 1493 1491 1493 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="3">OS</th>
###xml 1477 1493 1477 1493 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th rowspan="2">&#160;</th><th colspan="3">CR rate</th><th colspan="3">EFS</th><th colspan="3">DFS</th><th colspan="3">OS</th></tr>
###xml 1493 1495 1493 1495 <th xmlns:xlink="http://www.w3.org/1999/xlink">OR</th>
###xml 1495 1501 1495 1501 <th xmlns:xlink="http://www.w3.org/1999/xlink">95% CI</th>
###xml 1501 1502 1501 1502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1501 1502 1501 1502 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>p</italic></th>
###xml 1502 1504 1502 1504 <th xmlns:xlink="http://www.w3.org/1999/xlink">HR</th>
###xml 1504 1510 1504 1510 <th xmlns:xlink="http://www.w3.org/1999/xlink">95% CI</th>
###xml 1510 1511 1510 1511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1510 1511 1510 1511 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>p</italic></th>
###xml 1511 1513 1511 1513 <th xmlns:xlink="http://www.w3.org/1999/xlink">HR</th>
###xml 1513 1519 1513 1519 <th xmlns:xlink="http://www.w3.org/1999/xlink">95% CI</th>
###xml 1519 1520 1519 1520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1519 1520 1519 1520 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>p</italic></th>
###xml 1520 1522 1520 1522 <th xmlns:xlink="http://www.w3.org/1999/xlink">HR</th>
###xml 1522 1528 1522 1528 <th xmlns:xlink="http://www.w3.org/1999/xlink">95% CI</th>
###xml 1528 1529 1528 1529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1528 1529 1528 1529 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>p</italic></th>
###xml 1493 1529 1493 1529 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>OR</th><th>95% CI</th><th><italic>p</italic></th><th>HR</th><th>95% CI</th><th><italic>p</italic></th><th>HR</th><th>95% CI</th><th><italic>p</italic></th><th>HR</th><th>95% CI</th><th><italic>p</italic></th></tr>
###xml 1477 1529 1477 1529 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th rowspan="2">&#160;</th><th colspan="3">CR rate</th><th colspan="3">EFS</th><th colspan="3">DFS</th><th colspan="3">OS</th></tr><tr><th>OR</th><th>95% CI</th><th><italic>p</italic></th><th>HR</th><th>95% CI</th><th><italic>p</italic></th><th>HR</th><th>95% CI</th><th><italic>p</italic></th><th>HR</th><th>95% CI</th><th><italic>p</italic></th></tr></thead>
###xml 1529 1533 1529 1533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 1529 1533 1529 1533 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>MDR1</italic></td>
###xml 1533 1533 1533 1533 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1533 1533 1533 1533 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1533 1533 1533 1533 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1533 1533 1533 1533 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1533 1533 1533 1533 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1533 1533 1533 1533 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1533 1533 1533 1533 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1533 1533 1533 1533 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1533 1533 1533 1533 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1533 1533 1533 1533 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1533 1533 1533 1533 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1533 1533 1533 1533 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1529 1533 1529 1533 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>MDR1</italic></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr>
###xml 1533 1544 1533 1544 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;Univariate</td>
###xml 1544 1548 1544 1548 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.75</td>
###xml 1548 1557 1548 1557 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.61&#8211;0.93</td>
###xml 1557 1562 1557 1562 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.009</td>
###xml 1562 1566 1562 1566 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">1.14</td>
###xml 1566 1575 1566 1575 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.03&#8211;1.27</td>
###xml 1575 1579 1575 1579 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.01</td>
###xml 1579 1583 1579 1583 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">1.13</td>
###xml 1583 1592 1583 1592 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.97&#8211;1.30</td>
###xml 1592 1596 1592 1596 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.11</td>
###xml 1596 1600 1596 1600 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">1.16</td>
###xml 1600 1609 1600 1609 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.05&#8211;1.29</td>
###xml 1609 1614 1609 1614 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.004</td>
###xml 1533 1614 1533 1614 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;Univariate</td><td align="center">0.75</td><td>0.61&#8211;0.93</td><td align="center">0.009</td><td align="center">1.14</td><td>1.03&#8211;1.27</td><td align="center">0.01</td><td align="center">1.13</td><td>0.97&#8211;1.30</td><td align="center">0.11</td><td align="center">1.16</td><td>1.05&#8211;1.29</td><td align="center">0.004</td></tr>
###xml 1614 1623 1614 1623 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;Adjusted</td>
###xml 1623 1627 1623 1627 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.77</td>
###xml 1627 1636 1627 1636 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.58&#8211;1.03</td>
###xml 1636 1640 1636 1640 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.08</td>
###xml 1640 1644 1640 1644 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">1.05</td>
###xml 1644 1653 1644 1653 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.91&#8211;1.21</td>
###xml 1653 1657 1653 1657 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.48</td>
###xml 1657 1661 1657 1661 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.95</td>
###xml 1661 1670 1661 1670 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.77&#8211;1.18</td>
###xml 1670 1674 1670 1674 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.67</td>
###xml 1674 1678 1674 1678 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">1.00</td>
###xml 1678 1687 1678 1687 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.87&#8211;1.16</td>
###xml 1687 1691 1687 1691 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.97</td>
###xml 1614 1691 1614 1691 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;Adjusted</td><td align="center">0.77</td><td>0.58&#8211;1.03</td><td align="center">0.08</td><td align="center">1.05</td><td>0.91&#8211;1.21</td><td align="center">0.48</td><td align="center">0.95</td><td>0.77&#8211;1.18</td><td align="center">0.67</td><td align="center">1.00</td><td>0.87&#8211;1.16</td><td align="center">0.97</td></tr>
###xml 1691 1695 1691 1695 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRP1</italic>
###xml 1691 1695 1691 1695 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>MRP1</italic></td>
###xml 1695 1695 1695 1695 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1695 1695 1695 1695 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1695 1695 1695 1695 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1695 1695 1695 1695 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1695 1695 1695 1695 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1695 1695 1695 1695 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1695 1695 1695 1695 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1695 1695 1695 1695 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1695 1695 1695 1695 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1695 1695 1695 1695 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1695 1695 1695 1695 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1695 1695 1695 1695 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1691 1695 1691 1695 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>MRP1</italic></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr>
###xml 1695 1706 1695 1706 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;Univariate</td>
###xml 1706 1710 1706 1710 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">1.06</td>
###xml 1710 1719 1710 1719 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.83&#8211;1.35</td>
###xml 1719 1723 1719 1723 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.63</td>
###xml 1723 1727 1723 1727 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">1.02</td>
###xml 1727 1736 1727 1736 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.90&#8211;1.15</td>
###xml 1736 1740 1736 1740 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.79</td>
###xml 1740 1744 1740 1744 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">1.07</td>
###xml 1744 1753 1744 1753 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.89&#8211;1.29</td>
###xml 1753 1757 1753 1757 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.47</td>
###xml 1757 1761 1757 1761 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">1.11</td>
###xml 1761 1770 1761 1770 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.97&#8211;1.26</td>
###xml 1770 1774 1770 1774 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.12</td>
###xml 1695 1774 1695 1774 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;Univariate</td><td align="center">1.06</td><td>0.83&#8211;1.35</td><td align="center">0.63</td><td align="center">1.02</td><td>0.90&#8211;1.15</td><td align="center">0.79</td><td align="center">1.07</td><td>0.89&#8211;1.29</td><td align="center">0.47</td><td align="center">1.11</td><td>0.97&#8211;1.26</td><td align="center">0.12</td></tr>
###xml 1774 1783 1774 1783 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;Adjusted</td>
###xml 1783 1787 1783 1787 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">1.22</td>
###xml 1787 1796 1787 1796 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.90&#8211;1.66</td>
###xml 1796 1800 1796 1800 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.20</td>
###xml 1800 1804 1800 1804 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">1.00</td>
###xml 1804 1813 1804 1813 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.87&#8211;1.15</td>
###xml 1813 1817 1813 1817 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.98</td>
###xml 1817 1821 1817 1821 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">1.12</td>
###xml 1821 1830 1821 1830 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.92&#8211;1.37</td>
###xml 1830 1834 1830 1834 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.26</td>
###xml 1834 1838 1834 1838 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">1.05</td>
###xml 1838 1847 1838 1847 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.91&#8211;1.21</td>
###xml 1847 1851 1847 1851 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.54</td>
###xml 1774 1851 1774 1851 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;Adjusted</td><td align="center">1.22</td><td>0.90&#8211;1.66</td><td align="center">0.20</td><td align="center">1.00</td><td>0.87&#8211;1.15</td><td align="center">0.98</td><td align="center">1.12</td><td>0.92&#8211;1.37</td><td align="center">0.26</td><td align="center">1.05</td><td>0.91&#8211;1.21</td><td align="center">0.54</td></tr>
###xml 1851 1854 1851 1854 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRP</italic>
###xml 1851 1854 1851 1854 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LRP</italic></td>
###xml 1854 1854 1854 1854 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1854 1854 1854 1854 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1854 1854 1854 1854 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1854 1854 1854 1854 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1854 1854 1854 1854 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1854 1854 1854 1854 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1854 1854 1854 1854 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1854 1854 1854 1854 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1854 1854 1854 1854 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1854 1854 1854 1854 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1854 1854 1854 1854 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1854 1854 1854 1854 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1851 1854 1851 1854 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>LRP</italic></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr>
###xml 1854 1865 1854 1865 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;Univariate</td>
###xml 1865 1869 1865 1869 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">1.16</td>
###xml 1869 1878 1869 1878 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.94&#8211;1.43</td>
###xml 1878 1882 1878 1882 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.16</td>
###xml 1882 1886 1882 1886 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.95</td>
###xml 1886 1895 1886 1895 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.86&#8211;1.06</td>
###xml 1895 1899 1895 1899 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.36</td>
###xml 1899 1903 1899 1903 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.98</td>
###xml 1903 1912 1903 1912 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.84&#8211;1.14</td>
###xml 1912 1916 1912 1916 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.79</td>
###xml 1916 1920 1916 1920 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.97</td>
###xml 1920 1929 1920 1929 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.87&#8211;1.08</td>
###xml 1929 1933 1929 1933 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.60</td>
###xml 1854 1933 1854 1933 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;Univariate</td><td align="center">1.16</td><td>0.94&#8211;1.43</td><td align="center">0.16</td><td align="center">0.95</td><td>0.86&#8211;1.06</td><td align="center">0.36</td><td align="center">0.98</td><td>0.84&#8211;1.14</td><td align="center">0.79</td><td align="center">0.97</td><td>0.87&#8211;1.08</td><td align="center">0.60</td></tr>
###xml 1933 1942 1933 1942 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;Adjusted</td>
###xml 1942 1946 1942 1946 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">1.22</td>
###xml 1946 1955 1946 1955 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.93&#8211;1.61</td>
###xml 1955 1959 1955 1959 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.15</td>
###xml 1959 1963 1959 1963 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.99</td>
###xml 1963 1972 1963 1972 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.87&#8211;1.12</td>
###xml 1972 1976 1972 1976 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.83</td>
###xml 1976 1980 1976 1980 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">1.06</td>
###xml 1980 1989 1980 1989 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.89&#8211;1.27</td>
###xml 1989 1993 1989 1993 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.52</td>
###xml 1993 1997 1993 1997 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.98</td>
###xml 1997 2006 1997 2006 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.86&#8211;1.12</td>
###xml 2006 2010 2006 2010 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.78</td>
###xml 1933 2010 1933 2010 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;Adjusted</td><td align="center">1.22</td><td>0.93&#8211;1.61</td><td align="center">0.15</td><td align="center">0.99</td><td>0.87&#8211;1.12</td><td align="center">0.83</td><td align="center">1.06</td><td>0.89&#8211;1.27</td><td align="center">0.52</td><td align="center">0.98</td><td>0.86&#8211;1.12</td><td align="center">0.78</td></tr>
###xml 2010 2014 2010 2014 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 2010 2014 2010 2014 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>BCRP</italic></td>
###xml 2014 2014 2014 2014 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2014 2014 2014 2014 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2014 2014 2014 2014 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2014 2014 2014 2014 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2014 2014 2014 2014 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2014 2014 2014 2014 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2014 2014 2014 2014 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2014 2014 2014 2014 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2014 2014 2014 2014 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2014 2014 2014 2014 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2014 2014 2014 2014 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2014 2014 2014 2014 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2010 2014 2010 2014 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>BCRP</italic></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr>
###xml 2014 2025 2014 2025 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;Univariate</td>
###xml 2025 2029 2025 2029 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.84</td>
###xml 2029 2038 2029 2038 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.66&#8211;1.06</td>
###xml 2038 2042 2038 2042 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.14</td>
###xml 2042 2046 2042 2046 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">1.04</td>
###xml 2046 2055 2046 2055 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.91&#8211;1.18</td>
###xml 2055 2059 2055 2059 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.58</td>
###xml 2059 2063 2059 2063 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.95</td>
###xml 2063 2072 2063 2072 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.77&#8211;1.16</td>
###xml 2072 2076 2072 2076 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.60</td>
###xml 2076 2080 2076 2080 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.96</td>
###xml 2080 2089 2080 2089 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.84&#8211;1.10</td>
###xml 2089 2093 2089 2093 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.58</td>
###xml 2014 2093 2014 2093 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;Univariate</td><td align="center">0.84</td><td>0.66&#8211;1.06</td><td align="center">0.14</td><td align="center">1.04</td><td>0.91&#8211;1.18</td><td align="center">0.58</td><td align="center">0.95</td><td>0.77&#8211;1.16</td><td align="center">0.60</td><td align="center">0.96</td><td>0.84&#8211;1.10</td><td align="center">0.58</td></tr>
###xml 2093 2102 2093 2102 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;Adjusted</td>
###xml 2102 2106 2102 2106 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.79</td>
###xml 2106 2116 2106 2116 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.59&#8211;1.06 </td>
###xml 2116 2120 2116 2120 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.12</td>
###xml 2120 2124 2120 2124 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.99</td>
###xml 2124 2133 2124 2133 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.86&#8211;1.14</td>
###xml 2133 2137 2133 2137 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.92</td>
###xml 2137 2141 2137 2141 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.84</td>
###xml 2141 2150 2141 2150 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.66&#8211;1.06</td>
###xml 2150 2154 2150 2154 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.14</td>
###xml 2154 2158 2154 2158 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.90</td>
###xml 2158 2167 2158 2167 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.77&#8211;1.05</td>
###xml 2167 2171 2167 2171 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.19</td>
###xml 2093 2171 2093 2171 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;Adjusted</td><td align="center">0.79</td><td>0.59&#8211;1.06 </td><td align="center">0.12</td><td align="center">0.99</td><td>0.86&#8211;1.14</td><td align="center">0.92</td><td align="center">0.84</td><td>0.66&#8211;1.06</td><td align="center">0.14</td><td align="center">0.90</td><td>0.77&#8211;1.05</td><td align="center">0.19</td></tr>
###xml 2171 2175 2171 2175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 2176 2180 2176 2180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 2171 2194 2171 2194 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>MDR1</italic>/<italic>BCRP</italic> co-expression</td>
###xml 2194 2194 2194 2194 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2194 2194 2194 2194 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2194 2194 2194 2194 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2194 2194 2194 2194 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2194 2194 2194 2194 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2194 2194 2194 2194 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2194 2194 2194 2194 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2194 2194 2194 2194 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2194 2194 2194 2194 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2194 2194 2194 2194 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2194 2194 2194 2194 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2194 2194 2194 2194 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2171 2194 2171 2194 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>MDR1</italic>/<italic>BCRP</italic> co-expression</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr>
###xml 2194 2205 2194 2205 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;Univariate</td>
###xml 2205 2209 2205 2209 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.38</td>
###xml 2209 2218 2209 2218 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.18&#8211;0.80</td>
###xml 2218 2222 2218 2222 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.01</td>
###xml 2222 2226 2222 2226 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">1.63</td>
###xml 2226 2235 2226 2235 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.11&#8211;2.37</td>
###xml 2235 2239 2235 2239 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.01</td>
###xml 2239 2243 2239 2243 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">1.65</td>
###xml 2243 2252 2243 2252 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.90&#8211;3.01</td>
###xml 2252 2256 2252 2256 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.11</td>
###xml 2256 2260 2256 2260 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">1.47</td>
###xml 2260 2269 2260 2269 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.00&#8211;2.16</td>
###xml 2269 2273 2269 2273 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.05</td>
###xml 2194 2273 2194 2273 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;Univariate</td><td align="center">0.38</td><td>0.18&#8211;0.80</td><td align="center">0.01</td><td align="center">1.63</td><td>1.11&#8211;2.37</td><td align="center">0.01</td><td align="center">1.65</td><td>0.90&#8211;3.01</td><td align="center">0.11</td><td align="center">1.47</td><td>1.00&#8211;2.16</td><td align="center">0.05</td></tr>
###xml 2273 2282 2273 2282 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;Adjusted</td>
###xml 2282 2286 2282 2286 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.37</td>
###xml 2286 2296 2286 2296 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.15&#8211;0.92 </td>
###xml 2296 2300 2296 2300 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.03</td>
###xml 2300 2304 2300 2304 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">1.53</td>
###xml 2304 2313 2304 2313 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.98&#8211;2.38</td>
###xml 2313 2317 2313 2317 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.06</td>
###xml 2317 2321 2317 2321 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">1.37</td>
###xml 2321 2330 2321 2330 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.67&#8211;2.82</td>
###xml 2330 2334 2330 2334 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.39</td>
###xml 2334 2338 2334 2338 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">1.16</td>
###xml 2338 2347 2338 2347 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.74&#8211;1.83</td>
###xml 2347 2351 2347 2351 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.51</td>
###xml 2273 2351 2273 2351 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;Adjusted</td><td align="center">0.37</td><td>0.15&#8211;0.92 </td><td align="center">0.03</td><td align="center">1.53</td><td>0.98&#8211;2.38</td><td align="center">0.06</td><td align="center">1.37</td><td>0.67&#8211;2.82</td><td align="center">0.39</td><td align="center">1.16</td><td>0.74&#8211;1.83</td><td align="center">0.51</td></tr>
###xml 1529 2351 1529 2351 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td><italic>MDR1</italic></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#160;Univariate</td><td align="center">0.75</td><td>0.61&#8211;0.93</td><td align="center">0.009</td><td align="center">1.14</td><td>1.03&#8211;1.27</td><td align="center">0.01</td><td align="center">1.13</td><td>0.97&#8211;1.30</td><td align="center">0.11</td><td align="center">1.16</td><td>1.05&#8211;1.29</td><td align="center">0.004</td></tr><tr><td>&#160;Adjusted</td><td align="center">0.77</td><td>0.58&#8211;1.03</td><td align="center">0.08</td><td align="center">1.05</td><td>0.91&#8211;1.21</td><td align="center">0.48</td><td align="center">0.95</td><td>0.77&#8211;1.18</td><td align="center">0.67</td><td align="center">1.00</td><td>0.87&#8211;1.16</td><td align="center">0.97</td></tr><tr><td><italic>MRP1</italic></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#160;Univariate</td><td align="center">1.06</td><td>0.83&#8211;1.35</td><td align="center">0.63</td><td align="center">1.02</td><td>0.90&#8211;1.15</td><td align="center">0.79</td><td align="center">1.07</td><td>0.89&#8211;1.29</td><td align="center">0.47</td><td align="center">1.11</td><td>0.97&#8211;1.26</td><td align="center">0.12</td></tr><tr><td>&#160;Adjusted</td><td align="center">1.22</td><td>0.90&#8211;1.66</td><td align="center">0.20</td><td align="center">1.00</td><td>0.87&#8211;1.15</td><td align="center">0.98</td><td align="center">1.12</td><td>0.92&#8211;1.37</td><td align="center">0.26</td><td align="center">1.05</td><td>0.91&#8211;1.21</td><td align="center">0.54</td></tr><tr><td><italic>LRP</italic></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#160;Univariate</td><td align="center">1.16</td><td>0.94&#8211;1.43</td><td align="center">0.16</td><td align="center">0.95</td><td>0.86&#8211;1.06</td><td align="center">0.36</td><td align="center">0.98</td><td>0.84&#8211;1.14</td><td align="center">0.79</td><td align="center">0.97</td><td>0.87&#8211;1.08</td><td align="center">0.60</td></tr><tr><td>&#160;Adjusted</td><td align="center">1.22</td><td>0.93&#8211;1.61</td><td align="center">0.15</td><td align="center">0.99</td><td>0.87&#8211;1.12</td><td align="center">0.83</td><td align="center">1.06</td><td>0.89&#8211;1.27</td><td align="center">0.52</td><td align="center">0.98</td><td>0.86&#8211;1.12</td><td align="center">0.78</td></tr><tr><td><italic>BCRP</italic></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#160;Univariate</td><td align="center">0.84</td><td>0.66&#8211;1.06</td><td align="center">0.14</td><td align="center">1.04</td><td>0.91&#8211;1.18</td><td align="center">0.58</td><td align="center">0.95</td><td>0.77&#8211;1.16</td><td align="center">0.60</td><td align="center">0.96</td><td>0.84&#8211;1.10</td><td align="center">0.58</td></tr><tr><td>&#160;Adjusted</td><td align="center">0.79</td><td>0.59&#8211;1.06 </td><td align="center">0.12</td><td align="center">0.99</td><td>0.86&#8211;1.14</td><td align="center">0.92</td><td align="center">0.84</td><td>0.66&#8211;1.06</td><td align="center">0.14</td><td align="center">0.90</td><td>0.77&#8211;1.05</td><td align="center">0.19</td></tr><tr><td><italic>MDR1</italic>/<italic>BCRP</italic> co-expression</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#160;Univariate</td><td align="center">0.38</td><td>0.18&#8211;0.80</td><td align="center">0.01</td><td align="center">1.63</td><td>1.11&#8211;2.37</td><td align="center">0.01</td><td align="center">1.65</td><td>0.90&#8211;3.01</td><td align="center">0.11</td><td align="center">1.47</td><td>1.00&#8211;2.16</td><td align="center">0.05</td></tr><tr><td>&#160;Adjusted</td><td align="center">0.37</td><td>0.15&#8211;0.92 </td><td align="center">0.03</td><td align="center">1.53</td><td>0.98&#8211;2.38</td><td align="center">0.06</td><td align="center">1.37</td><td>0.67&#8211;2.82</td><td align="center">0.39</td><td align="center">1.16</td><td>0.74&#8211;1.83</td><td align="center">0.51</td></tr></tbody>
###xml 1477 2351 1477 2351 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th rowspan="2">&#160;</th><th colspan="3">CR rate</th><th colspan="3">EFS</th><th colspan="3">DFS</th><th colspan="3">OS</th></tr><tr><th>OR</th><th>95% CI</th><th><italic>p</italic></th><th>HR</th><th>95% CI</th><th><italic>p</italic></th><th>HR</th><th>95% CI</th><th><italic>p</italic></th><th>HR</th><th>95% CI</th><th><italic>p</italic></th></tr></thead><tbody><tr><td><italic>MDR1</italic></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#160;Univariate</td><td align="center">0.75</td><td>0.61&#8211;0.93</td><td align="center">0.009</td><td align="center">1.14</td><td>1.03&#8211;1.27</td><td align="center">0.01</td><td align="center">1.13</td><td>0.97&#8211;1.30</td><td align="center">0.11</td><td align="center">1.16</td><td>1.05&#8211;1.29</td><td align="center">0.004</td></tr><tr><td>&#160;Adjusted</td><td align="center">0.77</td><td>0.58&#8211;1.03</td><td align="center">0.08</td><td align="center">1.05</td><td>0.91&#8211;1.21</td><td align="center">0.48</td><td align="center">0.95</td><td>0.77&#8211;1.18</td><td align="center">0.67</td><td align="center">1.00</td><td>0.87&#8211;1.16</td><td align="center">0.97</td></tr><tr><td><italic>MRP1</italic></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#160;Univariate</td><td align="center">1.06</td><td>0.83&#8211;1.35</td><td align="center">0.63</td><td align="center">1.02</td><td>0.90&#8211;1.15</td><td align="center">0.79</td><td align="center">1.07</td><td>0.89&#8211;1.29</td><td align="center">0.47</td><td align="center">1.11</td><td>0.97&#8211;1.26</td><td align="center">0.12</td></tr><tr><td>&#160;Adjusted</td><td align="center">1.22</td><td>0.90&#8211;1.66</td><td align="center">0.20</td><td align="center">1.00</td><td>0.87&#8211;1.15</td><td align="center">0.98</td><td align="center">1.12</td><td>0.92&#8211;1.37</td><td align="center">0.26</td><td align="center">1.05</td><td>0.91&#8211;1.21</td><td align="center">0.54</td></tr><tr><td><italic>LRP</italic></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#160;Univariate</td><td align="center">1.16</td><td>0.94&#8211;1.43</td><td align="center">0.16</td><td align="center">0.95</td><td>0.86&#8211;1.06</td><td align="center">0.36</td><td align="center">0.98</td><td>0.84&#8211;1.14</td><td align="center">0.79</td><td align="center">0.97</td><td>0.87&#8211;1.08</td><td align="center">0.60</td></tr><tr><td>&#160;Adjusted</td><td align="center">1.22</td><td>0.93&#8211;1.61</td><td align="center">0.15</td><td align="center">0.99</td><td>0.87&#8211;1.12</td><td align="center">0.83</td><td align="center">1.06</td><td>0.89&#8211;1.27</td><td align="center">0.52</td><td align="center">0.98</td><td>0.86&#8211;1.12</td><td align="center">0.78</td></tr><tr><td><italic>BCRP</italic></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#160;Univariate</td><td align="center">0.84</td><td>0.66&#8211;1.06</td><td align="center">0.14</td><td align="center">1.04</td><td>0.91&#8211;1.18</td><td align="center">0.58</td><td align="center">0.95</td><td>0.77&#8211;1.16</td><td align="center">0.60</td><td align="center">0.96</td><td>0.84&#8211;1.10</td><td align="center">0.58</td></tr><tr><td>&#160;Adjusted</td><td align="center">0.79</td><td>0.59&#8211;1.06 </td><td align="center">0.12</td><td align="center">0.99</td><td>0.86&#8211;1.14</td><td align="center">0.92</td><td align="center">0.84</td><td>0.66&#8211;1.06</td><td align="center">0.14</td><td align="center">0.90</td><td>0.77&#8211;1.05</td><td align="center">0.19</td></tr><tr><td><italic>MDR1</italic>/<italic>BCRP</italic> co-expression</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#160;Univariate</td><td align="center">0.38</td><td>0.18&#8211;0.80</td><td align="center">0.01</td><td align="center">1.63</td><td>1.11&#8211;2.37</td><td align="center">0.01</td><td align="center">1.65</td><td>0.90&#8211;3.01</td><td align="center">0.11</td><td align="center">1.47</td><td>1.00&#8211;2.16</td><td align="center">0.05</td></tr><tr><td>&#160;Adjusted</td><td align="center">0.37</td><td>0.15&#8211;0.92 </td><td align="center">0.03</td><td align="center">1.53</td><td>0.98&#8211;2.38</td><td align="center">0.06</td><td align="center">1.37</td><td>0.67&#8211;2.82</td><td align="center">0.39</td><td align="center">1.16</td><td>0.74&#8211;1.83</td><td align="center">0.51</td></tr></tbody></table>
###xml 2544 2545 2544 2545 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2695 2699 2695 2699 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 2701 2705 2701 2705 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRP1</italic>
###xml 2707 2710 2707 2710 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRP</italic>
###xml 2716 2720 2716 2720 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 2775 2779 2775 2779 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 2780 2784 2780 2784 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 2351 2799 2351 2799 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="36">Results of logistic (for CR rate) and Cox regression (for survival) analyses, either univariate (=unadjusted) or adjusted for treatment arm, secondary AML, WBC count (natural logarithm), % CD34<sup>+</sup> (square root), and cytogenetic risk (favorable/intermediate versus unfavorable versus unknown), are shown for each of the four drug resistance genes <italic>MDR1</italic>, <italic>MRP1</italic>, <italic>LRP</italic>, and <italic>BCRP</italic> (natural logarithm of mRNA expression levels) and for <italic>MDR1</italic>/<italic>BCRP</italic> co-expression.</p>
###xml 2351 2799 2351 2799 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="36">Results of logistic (for CR rate) and Cox regression (for survival) analyses, either univariate (=unadjusted) or adjusted for treatment arm, secondary AML, WBC count (natural logarithm), % CD34<sup>+</sup> (square root), and cytogenetic risk (favorable/intermediate versus unfavorable versus unknown), are shown for each of the four drug resistance genes <italic>MDR1</italic>, <italic>MRP1</italic>, <italic>LRP</italic>, and <italic>BCRP</italic> (natural logarithm of mRNA expression levels) and for <italic>MDR1</italic>/<italic>BCRP</italic> co-expression.</p></table-wrap-foot>
###xml 1378 2799 1378 2799 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab3"><label>Table&#160;3</label><caption><p textid="35">Prognostic value of drug resistance gene expression w.r.t. CR rate, EFS, DFS from CR, and OS</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">&#160;</th><th colspan="3">CR rate</th><th colspan="3">EFS</th><th colspan="3">DFS</th><th colspan="3">OS</th></tr><tr><th>OR</th><th>95% CI</th><th><italic>p</italic></th><th>HR</th><th>95% CI</th><th><italic>p</italic></th><th>HR</th><th>95% CI</th><th><italic>p</italic></th><th>HR</th><th>95% CI</th><th><italic>p</italic></th></tr></thead><tbody><tr><td><italic>MDR1</italic></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#160;Univariate</td><td align="center">0.75</td><td>0.61&#8211;0.93</td><td align="center">0.009</td><td align="center">1.14</td><td>1.03&#8211;1.27</td><td align="center">0.01</td><td align="center">1.13</td><td>0.97&#8211;1.30</td><td align="center">0.11</td><td align="center">1.16</td><td>1.05&#8211;1.29</td><td align="center">0.004</td></tr><tr><td>&#160;Adjusted</td><td align="center">0.77</td><td>0.58&#8211;1.03</td><td align="center">0.08</td><td align="center">1.05</td><td>0.91&#8211;1.21</td><td align="center">0.48</td><td align="center">0.95</td><td>0.77&#8211;1.18</td><td align="center">0.67</td><td align="center">1.00</td><td>0.87&#8211;1.16</td><td align="center">0.97</td></tr><tr><td><italic>MRP1</italic></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#160;Univariate</td><td align="center">1.06</td><td>0.83&#8211;1.35</td><td align="center">0.63</td><td align="center">1.02</td><td>0.90&#8211;1.15</td><td align="center">0.79</td><td align="center">1.07</td><td>0.89&#8211;1.29</td><td align="center">0.47</td><td align="center">1.11</td><td>0.97&#8211;1.26</td><td align="center">0.12</td></tr><tr><td>&#160;Adjusted</td><td align="center">1.22</td><td>0.90&#8211;1.66</td><td align="center">0.20</td><td align="center">1.00</td><td>0.87&#8211;1.15</td><td align="center">0.98</td><td align="center">1.12</td><td>0.92&#8211;1.37</td><td align="center">0.26</td><td align="center">1.05</td><td>0.91&#8211;1.21</td><td align="center">0.54</td></tr><tr><td><italic>LRP</italic></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#160;Univariate</td><td align="center">1.16</td><td>0.94&#8211;1.43</td><td align="center">0.16</td><td align="center">0.95</td><td>0.86&#8211;1.06</td><td align="center">0.36</td><td align="center">0.98</td><td>0.84&#8211;1.14</td><td align="center">0.79</td><td align="center">0.97</td><td>0.87&#8211;1.08</td><td align="center">0.60</td></tr><tr><td>&#160;Adjusted</td><td align="center">1.22</td><td>0.93&#8211;1.61</td><td align="center">0.15</td><td align="center">0.99</td><td>0.87&#8211;1.12</td><td align="center">0.83</td><td align="center">1.06</td><td>0.89&#8211;1.27</td><td align="center">0.52</td><td align="center">0.98</td><td>0.86&#8211;1.12</td><td align="center">0.78</td></tr><tr><td><italic>BCRP</italic></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#160;Univariate</td><td align="center">0.84</td><td>0.66&#8211;1.06</td><td align="center">0.14</td><td align="center">1.04</td><td>0.91&#8211;1.18</td><td align="center">0.58</td><td align="center">0.95</td><td>0.77&#8211;1.16</td><td align="center">0.60</td><td align="center">0.96</td><td>0.84&#8211;1.10</td><td align="center">0.58</td></tr><tr><td>&#160;Adjusted</td><td align="center">0.79</td><td>0.59&#8211;1.06 </td><td align="center">0.12</td><td align="center">0.99</td><td>0.86&#8211;1.14</td><td align="center">0.92</td><td align="center">0.84</td><td>0.66&#8211;1.06</td><td align="center">0.14</td><td align="center">0.90</td><td>0.77&#8211;1.05</td><td align="center">0.19</td></tr><tr><td><italic>MDR1</italic>/<italic>BCRP</italic> co-expression</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#160;Univariate</td><td align="center">0.38</td><td>0.18&#8211;0.80</td><td align="center">0.01</td><td align="center">1.63</td><td>1.11&#8211;2.37</td><td align="center">0.01</td><td align="center">1.65</td><td>0.90&#8211;3.01</td><td align="center">0.11</td><td align="center">1.47</td><td>1.00&#8211;2.16</td><td align="center">0.05</td></tr><tr><td>&#160;Adjusted</td><td align="center">0.37</td><td>0.15&#8211;0.92 </td><td align="center">0.03</td><td align="center">1.53</td><td>0.98&#8211;2.38</td><td align="center">0.06</td><td align="center">1.37</td><td>0.67&#8211;2.82</td><td align="center">0.39</td><td align="center">1.16</td><td>0.74&#8211;1.83</td><td align="center">0.51</td></tr></tbody></table><table-wrap-foot><p textid="36">Results of logistic (for CR rate) and Cox regression (for survival) analyses, either univariate (=unadjusted) or adjusted for treatment arm, secondary AML, WBC count (natural logarithm), % CD34<sup>+</sup> (square root), and cytogenetic risk (favorable/intermediate versus unfavorable versus unknown), are shown for each of the four drug resistance genes <italic>MDR1</italic>, <italic>MRP1</italic>, <italic>LRP</italic>, and <italic>BCRP</italic> (natural logarithm of mRNA expression levels) and for <italic>MDR1</italic>/<italic>BCRP</italic> co-expression.</p></table-wrap-foot></table-wrap>
###xml 2799 2805 2799 2805 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 2871 2875 2871 2875 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 2880 2889 2880 2889 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP mRNA</italic>
###xml 2891 2892 2891 2892 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 2914 2915 2914 2915 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 2939 2940 2939 2940 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 2959 2962 2959 2962 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pos</italic>
###xml 3003 3007 3003 3007 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 3012 3016 3012 3016 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 3022 3027 3022 3027 <italic xmlns:xlink="http://www.w3.org/1999/xlink">other</italic>
###xml 2805 3058 2805 3058 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="37">Survival of elderly AML patients with and without coexpression of <italic>MDR1</italic> and <italic>BCRP mRNA</italic>. <bold>a</bold> Event-free survival, <bold>b</bold> disease-free survival, <bold>c</bold> overall survival. <italic>pos</italic> indicates patients with coexpression of <italic>MDR1</italic> and <italic>BCRP</italic>; and <italic>other</italic>, patients without coexpression</p>
###xml 2805 3058 2805 3058 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="37">Survival of elderly AML patients with and without coexpression of <italic>MDR1</italic> and <italic>BCRP mRNA</italic>. <bold>a</bold> Event-free survival, <bold>b</bold> disease-free survival, <bold>c</bold> overall survival. <italic>pos</italic> indicates patients with coexpression of <italic>MDR1</italic> and <italic>BCRP</italic>; and <italic>other</italic>, patients without coexpression</p></caption>
###xml 3058 3058 3058 3058 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="277_2007_269_Fig2_HTML" id="MO2"/>
###xml 2799 3058 2799 3058 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="37">Survival of elderly AML patients with and without coexpression of <italic>MDR1</italic> and <italic>BCRP mRNA</italic>. <bold>a</bold> Event-free survival, <bold>b</bold> disease-free survival, <bold>c</bold> overall survival. <italic>pos</italic> indicates patients with coexpression of <italic>MDR1</italic> and <italic>BCRP</italic>; and <italic>other</italic>, patients without coexpression</p></caption><graphic position="anchor" xlink:href="277_2007_269_Fig2_HTML" id="MO2"/></fig>
###xml 181 189 <span type="species:ncbi:9606">patients</span>
###xml 2829 2837 <span type="species:ncbi:9606">patients</span>
###xml 2973 2981 <span type="species:ncbi:9606">patients</span>
###xml 3029 3037 <span type="species:ncbi:9606">patients</span>
To assess the clinical relevance of the four resistance genes, their expression was evaluated with regard to CR rate and survival data, respectively. The median follow-up of the 25 patients still alive was 58 months (range, 1-80 months). Univariate logistic regression analysis showed that higher MDR1 mRNA expression predicted for a lower CR rate (log[MDR1]: odds ratio [OR]=0.75, 95% confidence interval [CI] 0.61-0.93, p = 0.009), whereas MRP1, LRP, and BCRP mRNA were not associated with CR (Fig. 1). MDR1 expression was also associated with a worse EFS (log[MDR1]: hazard ratio [HR]=1.14, 95% CI 1.03-1.27, p = 0.01) and OS (log[MDR1]: HR = 1.16, 95% CI 1.05-1.29, p = 0.004). Similar results were also obtained for MDR1/BCRP coexpression (Table 3; Fig. 2). When the analyses were performed with adjustment for other prognostic factors, as described in the "Statistical analysis", only MDR1/BCRP mRNA coexpression remained significantly associated with a lower CR rate (OR = 0.37, 95% CI 0.15-0.91, p = 0.03), whereas a trend was observed for worse EFS (Table 3). On the other hand, higher CD34 expression was significantly associated with a lower CR rate (square root[CD34]: OR = 0.86, 95% CI 0.76-0.98, p = 0.02) and with worse EFS (HR = 1.12, 95% CI 1.06-1.19, p < 0.001), DFS (HR = 1.19, 95% CI 1.09-1.30, p < 0.001), and OS (HR = 1.17, 95% CI = 1.10-1.25, p < 0.001). Table 3Prognostic value of drug resistance gene expression w.r.t. CR rate, EFS, DFS from CR, and OS CR rateEFSDFSOSOR95% CIpHR95% CIpHR95% CIpHR95% CIpMDR1 Univariate0.750.61-0.930.0091.141.03-1.270.011.130.97-1.300.111.161.05-1.290.004 Adjusted0.770.58-1.030.081.050.91-1.210.480.950.77-1.180.671.000.87-1.160.97MRP1 Univariate1.060.83-1.350.631.020.90-1.150.791.070.89-1.290.471.110.97-1.260.12 Adjusted1.220.90-1.660.201.000.87-1.150.981.120.92-1.370.261.050.91-1.210.54LRP Univariate1.160.94-1.430.160.950.86-1.060.360.980.84-1.140.790.970.87-1.080.60 Adjusted1.220.93-1.610.150.990.87-1.120.831.060.89-1.270.520.980.86-1.120.78BCRP Univariate0.840.66-1.060.141.040.91-1.180.580.950.77-1.160.600.960.84-1.100.58 Adjusted0.790.59-1.06 0.120.990.86-1.140.920.840.66-1.060.140.900.77-1.050.19MDR1/BCRP co-expression Univariate0.380.18-0.800.011.631.11-2.370.011.650.90-3.010.111.471.00-2.160.05 Adjusted0.370.15-0.92 0.031.530.98-2.380.061.370.67-2.820.391.160.74-1.830.51Results of logistic (for CR rate) and Cox regression (for survival) analyses, either univariate (=unadjusted) or adjusted for treatment arm, secondary AML, WBC count (natural logarithm), % CD34+ (square root), and cytogenetic risk (favorable/intermediate versus unfavorable versus unknown), are shown for each of the four drug resistance genes MDR1, MRP1, LRP, and BCRP (natural logarithm of mRNA expression levels) and for MDR1/BCRP co-expression.Fig. 2Survival of elderly AML patients with and without coexpression of MDR1 and BCRP mRNA. a Event-free survival, b disease-free survival, c overall survival. pos indicates patients with coexpression of MDR1 and BCRP; and other, patients without coexpression
###end p 34
###begin p 35
Prognostic value of drug resistance gene expression w.r.t. CR rate, EFS, DFS from CR, and OS
###end p 35
###begin p 36
###xml 193 194 193 194 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 344 348 344 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 350 354 350 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRP1</italic>
###xml 356 359 356 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRP</italic>
###xml 365 369 365 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 424 428 424 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 429 433 429 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
Results of logistic (for CR rate) and Cox regression (for survival) analyses, either univariate (=unadjusted) or adjusted for treatment arm, secondary AML, WBC count (natural logarithm), % CD34+ (square root), and cytogenetic risk (favorable/intermediate versus unfavorable versus unknown), are shown for each of the four drug resistance genes MDR1, MRP1, LRP, and BCRP (natural logarithm of mRNA expression levels) and for MDR1/BCRP co-expression.
###end p 36
###begin p 37
###xml 66 70 66 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 75 84 75 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP mRNA</italic>
###xml 86 87 86 87 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 109 110 109 110 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 134 135 134 135 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 154 157 154 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pos</italic>
###xml 198 202 198 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 207 211 207 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 217 222 217 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">other</italic>
###xml 24 32 <span type="species:ncbi:9606">patients</span>
###xml 168 176 <span type="species:ncbi:9606">patients</span>
###xml 224 232 <span type="species:ncbi:9606">patients</span>
Survival of elderly AML patients with and without coexpression of MDR1 and BCRP mRNA. a Event-free survival, b disease-free survival, c overall survival. pos indicates patients with coexpression of MDR1 and BCRP; and other, patients without coexpression
###end p 37
###begin title 38
Discussion
###end title 38
###begin p 39
###xml 184 186 184 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 330 331 330 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 332 334 332 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 336 338 336 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 363 367 363 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRP1</italic>
###xml 369 372 369 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRP</italic>
###xml 378 382 378 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 788 789 788 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 982 983 982 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 985 986 985 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 988 989 988 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 991 993 991 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 994 996 994 996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 1088 1092 1088 1092 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 1171 1175 1171 1175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 1188 1190 1188 1190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 1192 1194 1192 1194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 1213 1215 1213 1215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 1229 1233 1229 1233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 1374 1378 1374 1378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 1473 1477 1473 1477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 1584 1586 1584 1586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 1606 1608 1606 1608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 1625 1629 1625 1629 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 1977 1981 1977 1981 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 111 119 <span type="species:ncbi:9606">patients</span>
###xml 440 448 <span type="species:ncbi:9606">patients</span>
###xml 573 580 <span type="species:ncbi:9606">patient</span>
###xml 1059 1067 <span type="species:ncbi:9606">patients</span>
###xml 1145 1153 <span type="species:ncbi:9606">patients</span>
###xml 1304 1312 <span type="species:ncbi:9606">patients</span>
###xml 1437 1445 <span type="species:ncbi:9606">children</span>
###xml 1505 1513 <span type="species:ncbi:9606">patients</span>
###xml 1733 1741 <span type="species:ncbi:9606">patients</span>
###xml 1754 1762 <span type="species:ncbi:9606">patients</span>
###xml 1842 1850 <span type="species:ncbi:9606">patients</span>
This is the first comprehensive analysis of the effect of the major classical MDR genes in a cohort of elderly patients with AML homogeneously treated in a prospective clinical trial [14]. A wide range of expression of the various resistance genes was observed, consistent with previous studies and with comparable median values [9-11, 23]. Our results show that MRP1, LRP, and BCRP are not associated with CR rate or survival endpoints in patients with AML aged 60 years or older, indicating that the clinical relevance of the expression of these genes is limited in this patient population. This study confirms previous reports, which showed the unique prognostic role of MDR1 expression-which was however highly correlated with CD34 expression-in drug resistance in elderly AML (Table 3), in contrast to the prognostic value of MRP1 expression in AML, which has shown conflicting results, whereas currently, LRP is no longer thought to be important for clinical drug resistance [4, 5, 7, 24-27]. Recently, two studies in, respectively, 40 and 31 adult AML patients showed no effect of BCRP gene expression on CR rate, whereas OS was lower in patients with the highest BCRP expression [10, 23]. Damiani et al. [28] showed that BCRP expression did not influence achievement of complete remission in AML patients with a median age of 53 years and normal karyotype, however, BCRP expression was associated with higher relapse rate. In 59 children with de novo AML, a higher BCRP expression was observed in patients who did not reach CR, but this was not translated in poorer survival [29]. Benderra et al. [19] indicated that BCRP gene expression was an adverse prognostic factor for CR in a group of 149 relatively younger adult AML patients but only in patients treated with DNR and MXT and not with idarubicin. In our cohort of elderly AML patients who were all treated with DNR, whereas MXT was given as consolidation therapy after reaching CR, a significant correlation of BCRP mRNA expression with lower CR rate could not be shown.
###end p 39
###begin p 40
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 33 37 33 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 186 187 186 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 188 190 188 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 192 194 192 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 278 282 278 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 287 291 287 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 364 366 364 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 368 370 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 390 392 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 464 468 464 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 473 477 473 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 514 518 514 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 519 523 519 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 555 564 555 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1/BCRP</italic>
###xml 574 575 574 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 647 651 647 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 652 656 652 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 682 684 682 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 752 756 752 756 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 758 762 758 762 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 908 912 908 912 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 917 921 917 921 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 1079 1081 1079 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 61 69 <span type="species:ncbi:9606">patients</span>
###xml 176 184 <span type="species:ncbi:9606">patients</span>
###xml 354 362 <span type="species:ncbi:9606">patients</span>
###xml 434 442 <span type="species:ncbi:9606">patients</span>
###xml 763 771 <span type="species:ncbi:9606">patients</span>
Our study confirms that BCRP and MDR1 are coexpressed in AML patients with higher age as has been suggested previously from studies in smaller groups of relatively younger AML patients [9-11, 28]. Until now, only two studies have evaluated the clinical value of coexpression of MDR1 and BCRP in a sufficient number, although relatively younger adult AML patients [19, 28]. Benderra et al. [19] showed that CR rate was only 45% in the patients with coexpression of BCRP and MDR1 (+/+) in comparison with 66% in the MDR1/BCRP-/+ and +/-group and 90% in the MDR1/BCRP-/-group (p = 0.003). Moreover, a significantly lower DFS and OS were found in the MDR1/BCRP+/+group. Damiani et al. [28] found a trend towards a higher relapse rate in the small group of BCRP+/MDR1+patients, indicating that this represents a robust resistant AML phenotype, consistent with our findings in elderly AML. The recent finding that BCRP and MDR1 expression was mainly found in the most resistant group of AML, using gene expression profiling, underscores the role of these drug resistance genes in AML [30].
###end p 40
###begin p 41
###xml 198 202 198 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 207 211 207 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 220 224 220 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRP1</italic>
###xml 229 232 229 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRP</italic>
###xml 356 360 356 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 695 699 695 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 773 775 773 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 777 779 777 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 847 851 847 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 856 860 856 860 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 908 910 908 910 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
###xml 911 913 911 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">34</xref>
###xml 928 932 928 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 1009 1013 1009 1013 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 1042 1043 1042 1043 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1048 1049 1048 1049 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1066 1067 1066 1067 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1072 1073 1072 1073 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1080 1082 1080 1082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 1084 1086 1084 1086 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">35</xref>
###xml 1120 1124 1120 1124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 1129 1133 1129 1133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 1262 1264 1262 1264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">36</xref>
###xml 1466 1468 1466 1468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 1573 1582 1573 1582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP/MDR1</italic>
###xml 1744 1745 1744 1745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 1752 1753 1752 1753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 324 332 <span type="species:ncbi:9606">patients</span>
###xml 636 644 <span type="species:ncbi:9606">patients</span>
###xml 814 818 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 1597 1605 <span type="species:ncbi:9606">patients</span>
However, this study shows, that the prominent prognostic role of CD34 expression in elderly AML should be emphasized, as higher CD34 expression was adversely associated with all clinical endpoints. MDR1 and BCRP but not MRP1 and LRP mRNA expression were found to be associated with high CD34 expression in these elderly AML patients, which may explain why MDR1 was no longer significant for CR rate, EFS, and OS when adjusted for other prognostic variables including CD34. In the past, MDR1 expression has been linked to the CD34-positive hematopoietic stem cell compartment of the leukemia subtype. In two other studies in younger AML patients, no overexpression (on mRNA and protein level) of BCRP in the CD34-positive blast population of clinical AML samples was found [13, 19]. In contrast, earlier studies in mice demonstrated high levels of BCRP and MDR1 expression in normal hematopoietic stem cells [31-34]. Previously, BCRP expression in subsets of stem cells has been reported, indicating that high BCRP expression may exist in CD34+/CD38- cells or in CD34+/CD33-cells [12, 35]. The differential expression of BCRP and MDR1 in specific subsets of hematopoietic stem cells is consistent with the side population phenotype as proposed by Goodell et al. [36] who claim that BCRP expression can be separated from those expressing the other ABC proteins. This would suggest that BCRP is expressed in even less differentiated hematopoietic stem cells than MDR1 [19]. In our study in AML, these immature subsets could not be separately investigated, however, the unique BCRP/MDR1+/+subgroup of patients reflects an immature leukemic cell type that has a very resistant phenotype in vivo, illustrated by a low CR rate and poor outcome (Table 3; Fig. 2).
###end p 41
###begin p 42
###xml 104 108 104 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 193 197 193 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 295 299 295 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 386 388 386 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 390 392 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 411 413 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR37">37</xref>
###xml 532 536 532 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 227 235 <span type="species:ncbi:9606">patients</span>
###xml 376 384 <span type="species:ncbi:9606">patients</span>
###xml 466 474 <span type="species:ncbi:9606">patients</span>
This is the first study in which a correlation was found between secondary AML and a high expression of BCRP mRNA but not the other resistance proteins. In addition to our previous report that BCRP is frequently upregulated in patients with AML at relapse, we now demonstrate that expression of BCRP is representative of secondary AML, which is especially observed in elderly patients [11, 29]. Recently, Ross [37] suggested that MDR modifiers may be of benefit for patients with multiple dysplastic features. This may suggest that BCRP is upregulated in diseases in which exposure to xenobiotics during life plays an etiologic role.
###end p 42
###begin p 43
###xml 62 66 62 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 71 75 71 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 157 161 157 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 332 336 332 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCRP</italic>
###xml 341 345 341 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDR1</italic>
###xml 265 273 <span type="species:ncbi:9606">patients</span>
We conclude that coexpression of CD34-related coexpression of MDR1 and BCRP reflects a clinically resistant subgroup of elderly AML. In this age group, only BCRP is correlated with secondary AML. As such, the development of new treatment strategies for elderly AML patients may focus on modulation of drug resistance targeting both BCRP and MDR1.
###end p 43
###begin title 44
Acknowledgements
###end title 44
###begin p 45
We acknowledge M. Schoester and A. Prins for their technical assistance and Dr. P.P. Piccaluga and Dr. P.J.M. Vossebeld for their contribution to this study.
###end p 45
###begin title 46
References
###end title 46
###begin article-title 47
Multidrug resistance gene expression in acute myeloid leukemia: major prognosis significance for in vivo drug resistance to induction treatment
###end article-title 47
###begin article-title 48
Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study
###end article-title 48
###begin article-title 49
MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia
###end article-title 49
###begin article-title 50
The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program
###end article-title 50
###begin article-title 51
Vaults: a ribonucleoprotein particle involved in drug resistance
###end article-title 51
###begin article-title 52
Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia
###end article-title 52
###begin article-title 53
Efflux kinetics and intracellular distribution of daunorubicin are not affected by major vault protein/lung resistance-related protein (vault) expression
###end article-title 53
###begin article-title 54
###xml 40 45 <span type="species:ncbi:9606">human</span>
A multidrug resistance transporter from human MCF-7 breast cancer cells
###end article-title 54
###begin article-title 55
###xml 67 75 <span type="species:ncbi:9606">patients</span>
Expression of breast cancer resistance protein in blast cells from patients with acute leukemia
###end article-title 55
###begin article-title 56
###xml 57 65 <span type="species:ncbi:9606">patients</span>
BCRP mRNA expression v. clinical outcome in 40 adult AML patients
###end article-title 56
###begin article-title 57
Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML)
###end article-title 57
###begin article-title 58
Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia
###end article-title 58
###begin article-title 59
Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia
###end article-title 59
###begin article-title 60
###xml 116 124 <span type="species:ncbi:9606">patients</span>
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis
###end article-title 60
###begin article-title 61
Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia
###end article-title 61
###begin article-title 62
Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia
###end article-title 62
###begin article-title 63
Regression models and life tables
###end article-title 63
###begin article-title 64
Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias
###end article-title 64
###begin article-title 65
Nonparametric estimation from incomplete observations
###end article-title 65
###begin article-title 66
Evaluation of survival data and two new rank order statistics arising in its consideration
###end article-title 66
###begin article-title 67
###xml 101 109 <span type="species:ncbi:9606">patients</span>
ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients
###end article-title 67
###begin article-title 68
Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survival
###end article-title 68
###begin article-title 69
Lung resistance protein (LRP) gene expression in adult acute myeloid leukemia: a critical evaluation by three techniques
###end article-title 69
###begin article-title 70
MDR-1 expression and deletions of chromosomes 7 and 5(Q) separately indicate adverse prognosis in AML
###end article-title 70
###begin article-title 71
Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia
###end article-title 71
###begin article-title 72
Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study
###end article-title 72
###begin article-title 73
The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype
###end article-title 73
###begin article-title 74
BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia
###end article-title 74
###begin article-title 75
Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction
###end article-title 75
###begin article-title 76
Low levels of ABCG2 expression in adult AML blast samples
###end article-title 76
###begin article-title 77
ABCG2 (BCRP) expression in normal and malignant hematopoietic cells
###end article-title 77
###begin article-title 78
A proposal for the physiological significance of mdr1 and Bcrp1/Abcg2 gene expression in normal tissue regeneration and after cancer therapy
###end article-title 78
###begin article-title 79
###xml 25 29 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Hematopoietic cells from mice that are deficient in both Bcrp1/Abcg2 and Mdr1a/1b develop normally but are sensitized to mitoxantrone
###end article-title 79
###begin article-title 80
Breast cancer resistance protein in drug resistance of primitive CD34+38-cells in acute myeloid leukemia
###end article-title 80
###begin article-title 81
Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species
###end article-title 81
###begin article-title 82
Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome
###end article-title 82

